Method for separating adeno-associated virus capsid and pre-screening method
Through the use of pre-screening method and anion exchange chromatography materials, the AAV capsid is separated by increasing conductivity gradient elution buffer, which solves the problems of diversity and parameter differences in the separation of adeno-associated virus capsids, and improves separation efficiency and purification Rate.
Patent Information
- Application Number
- CN202380036413.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-27
- Filing Date
- 2023-04-26
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to efficiently and scalably isolate the complete and incomplete packaging of adeno-associated virus (AAV) capsids, especially the purification challenges resulting from the diversity of capsids and parameter differences generated during cell culture.
The appropriate elution conditions were determined to separate the AAV capsids in complete packaging and incomplete packaging by using a pre-screening method through anion exchange chromatography material and a step gradient elution buffer with increasing conductivity, and the separation capacity of the chromatography material was enhanced by using surface extension agents. .
The resolution of complete packaging capsids and incomplete packaging capsids is improved, and the purification of complete packaging capsids at a high ratio is achieved, reducing the cost and time of the separation process.
Smart Images

Figure CN119095608A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of separating adeno-associated capsids, and to a method for determining elution conditions suitable for separating adeno-associated viral capsids that fully package genetic material from adeno-associated viral capsids that incompletely package genetic material. Further disclosed are methods for separating adeno-associated viral capsids that fully package genetic material from adeno-associated viral capsids that incompletely package genetic material, and the use of anion exchange chromatography materials for such separations. The present disclosure can be applied to the separation of capsids of adeno-associated virus serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 (AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAV10) and variants thereof. Background Art
[0002] Adeno-associated virus (AAV) is a non-enveloped virus with a linear single-stranded DNA (ssDNA) genome and can be engineered to deliver DNA to target cells. Recombinant adeno-associated virus (rAAV) vectors have become one of the most versatile and successful gene therapy delivery vectors. The demand for gene therapy using viral vectors is increasing. In order to use AAV particles as vectors in therapy, it is necessary to purify viral particles after transfection to remove cell impurities such as DNA. Ultracentrifugation is efficient but not scalable. Typically, several filtration steps and several chromatographic steps are used to separate AAV particles from cell culture (see, e.g., Weihong Qu et al.).
[0003] The therapeutic efficacy of AAV vectors depends on a high percentage of virus particles that fully package the genetic material of interest. The upstream expression system provides a mixture of fully packaged AAV particles (containing the genetic material of interest), empty AAV particles, and AAV particles that partially package the genetic material of interest, as well as impurities. Therefore, it is necessary to enrich the fully packaged AAV particles during the purification process. However, there are several challenges in achieving efficient and scalable separation of fully packaged and empty adeno-associated virus capsids, such as:
[0004] - The huge diversity of capsids (serotypes and variants) and cell culture differences in intact capsid yields means that extensive optimization is required to purify each serotype or variant of AAV;
[0005] - The differences between fully packaged capsids and empty capsids are small in several parameters relevant for purification (e.g., isoelectric point);
[0006] - In addition to fully packaged capsids and empty capsids, partially packaged capsid variants are also produced in infected host cells. There are indications that such partially packaged and therefore less therapeutically effective capsids can co-elute with the fully packaged capsid fraction.
[0007] Methods for separating fully packaged capsids from incompletely packaged capsids have been described previously (see, e.g., Hejmowski et al.) However, further optimization of purification strategies is always needed to increase the speed and reduce the cost of downstream processing of different AAV serotypes. Summary of the invention
[0008] The object of the present disclosure is to provide an improved method for separating completely packaged adeno-associated virus capsids from incompletely packaged adeno-associated virus capsids. This is achieved by first performing a method for determining elution conditions suitable for separating completely packaged capsids from incompletely packaged capsids. In this article, this method is referred to as a pre-screening method. Then, a method for separating completely packaged capsids from incompletely packaged capsids is performed by eluting incompletely packaged capsids at a first conductivity value as determined in the pre-screening method, and by eluting completely packaged capsids at a second conductivity value as determined in the pre-screening method. An improved resolution between completely packaged capsids and incompletely packaged capsids is thereby obtained, which results in a composition having a higher ratio of completely packaged capsids to incompletely packaged capsids. The focus of the present disclosure is a pre-screening method for establishing the optimal elution conditions for the refining step (also known as secondary purification or final purification) of a separation method.
[0009] More specifically, a first aspect of the present disclosure relates to a so-called pre-screening method, which is a method for determining elution conditions suitable for separating adeno-associated virus (AAV) capsids that fully package genetic material from AAV capsids that incompletely package genetic material, the method comprising:
[0010] (a) adding a liquid sample comprising AAV capsids to a strong or partially strong anion exchange chromatography material comprising a surface extender,
[0011] (b) eluting the AAV viral capsids from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein each step increases in conductivity by about 0.5 to about 3 mS / cm,
[0012] (c) determining, based on the elution curve obtained in step (b), a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not fully package genetic material, and
[0013] (d) based on the elution curve obtained in step (b), determining a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that are intactly packaged with genetic material.
[0014] Even more specifically, the pre-screening method is a method for determining elution conditions suitable for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method comprising the steps of:
[0015] a) will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml is added to a strong or partially strong anion exchange chromatography material, the anion exchange chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids, wherein at least 5%, such as 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material,
[0016] wherein the chromatographic material comprises a surface extending agent that links the ligand to the support, wherein the surface extending agent is a polymer, wherein the polymer is selected from:
[0017] (i) polymers with naturally occurring backbones, such as polysaccharides, for example starch, cellulose, dextran or agarose; and
[0018] (ii) polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether;
[0019] b) eluting adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein the conductivity starts at about 0 to about 5 mS / cm and increases by about 0.5 to about 3 mS / cm per step, such as by about 1 to about 2 mS / cm per step, such as by about 1.2 to about 1.5 mS / cm per step, at least up to and including the conductivity at which adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material have been eluted from the chromatography material;
[0020] c) determining, based on the elution curve obtained in step (b), a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not fully package genetic material, and
[0021] d) based on the elution curve obtained in step (b), determining a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that are intactly packaged with genetic material.
[0022] The present disclosure further provides a method for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method comprising steps (a) to (d) of the above pre-screening method, and further comprising the following steps:
[0023] e. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml of adeno-associated virus capsids is added to the chromatographic material as defined in step (a), wherein at least 5%, for example 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material, the liquid sample being derived from the cell culture harvest from which the liquid sample of step (a) is derived;
[0024] f. eluting adeno-associated viral capsids that are incompletely packaged with genetic material by applying an elution buffer having a first value of conductivity or a conductivity-related parameter as determined in step (c); and
[0025] g. eluting the adeno-associated virus capsids intactly packaged with genetic material by applying an elution buffer having a second value of conductivity or a conductivity-related parameter as determined in step (d);
[0026] in
[0027] (i) the duration of step (f) is at least 3 times, for example 4 times, the duration of step (g), and / or
[0028] (ii) the method comprises a step (f') between step (f) and step (g), wherein step (f') comprises applying a further step elution and / or an increasing conductivity gradient between a first value and a second value of the conductivity or a conductivity-related parameter, and the duration of steps (f) and (f') is at least 3 times, for example 4 times, the duration of step (g).
[0029] In addition, the present disclosure relates to a method for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method comprising:
[0030] (I) will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml is added to a strong or partially strong anion exchange chromatography material, the chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids, wherein at least 5%, such as 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material,
[0031] wherein the chromatographic material comprises a surface extending agent linking the ligand to the support, wherein the surface extending agent is a polymer, wherein the polymer is selected from:
[0032] (i) polymers having a naturally occurring backbone, such as a polysaccharide, for example starch, cellulose, dextran or agarose, and
[0033] (ii) polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether;
[0034] (II) eluting adeno-associated virus capsids that incompletely package genetic material by applying an elution buffer having a predetermined first value of conductivity or a conductivity-related parameter;
[0035] (III) eluting the intact adeno-associated virus capsids packaging the genetic material by applying an elution buffer having a predetermined second value of conductivity or a conductivity-related parameter;
[0036] The predetermined first and second values of conductivity or a conductivity-related parameter are present in a sample having a purity of at least 90% and a concentration of at least 10 12 adeno-associated virus capsids / ml, wherein at least 5%, for example 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that are intact and packaged with genetic material, the liquid sample being derived from the cell culture harvest from which the liquid sample of step (I) is derived; optionally having been determined by performing steps (a) to (d) of the above-mentioned pre-screening method;
[0037] in
[0038] (i) the duration of step (II) is at least 3 times, for example 4 times, the duration of step (III), and / or
[0039] (ii) The method comprises a step (II') between step (II) and step (III), wherein step (II') comprises applying a step elution and / or an increasing conductivity gradient between a first value and a second value of conductivity or a conductivity-related parameter, and the duration of steps (II) and (II') is at least 3 times, for example 4 times, the duration of step (III).
[0040] The present disclosure also provides the use of an anion exchange chromatography material for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, wherein the anion exchange chromatography material comprises a support, a ligand, and a surface extender that connects the ligand to the support, and is defined by Formula IV:
[0041]
[0042] The method comprises determining elution conditions suitable for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material,
[0043] The elution conditions are determined by performing the following steps:
[0044] a. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids with a concentration of 100 adeno-associated virus capsids / ml is added to the chromatographic material, wherein at least 5%, such as 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material;
[0045] b. eluting adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein the conductivity starts at about 0 to about 5 mS / cm and increases by about 0.5 to about 3 mS / cm per step, such as by about 1 to about 2 mS / cm per step, such as by about 1.2 to about 1.5 mS / cm per step, at least up to and including the conductivity at which adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material have been eluted from the chromatography material;
[0046] c. based on the elution curve obtained in step (b), determining a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not completely package genetic material, and
[0047] d. Based on the elution curve obtained in step (b), determine a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that fully package genetic material.
[0048] Preferred aspects of the disclosure are described below in the detailed description and dependent claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 is a flow chart of a pre-screening method, ie, a method according to the present disclosure for determining elution conditions suitable for isolating adeno-associated virus capsids.
[0051] Figure 2 is a flow chart of a method for isolating adeno-associated virus capsids, the method comprising: Figure 1 The method comprises steps (a)-(d) of the pre-screening method and further comprises steps (e)-(g) according to the present disclosure.
[0052] Figure 3 is a flow chart of a method for isolating adeno-associated virus capsids according to the present disclosure, the method comprising applying a predetermined conductivity value.
[0053] Figure 4 is a graph showing the elution profiles for fully packaged capsids and empty capsids according to the separation method as described in Example 1 below.
[0054] Figure 5is a graph showing the elution profiles for fully packaged capsids and empty capsids according to the separation method as described in Example 1 below.
[0055] Figure 6 is a graph showing the elution profiles for fully packaged capsids and empty capsids according to the separation method as described in Example 1 below.
[0056] Figure 7 is a graph showing the elution profiles for fully packaged capsids and empty capsids according to the separation method as described in Example 2 below. DETAILED DESCRIPTION
[0057] The present disclosure provides Figure 1 The pre-screening method illustrated in the claims, i.e., a method for determining elution conditions suitable for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material, solves or at least alleviates the problems associated with existing methods for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material, comprises the following steps:
[0058] a) will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml is added to a strong or partially strong anion exchange chromatography material, the anion exchange chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids, wherein at least 5%, such as 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material,
[0059] wherein the chromatographic material comprises a surface extending agent that links the ligand to the support, wherein the surface extending agent is a polymer, wherein the polymer is selected from:
[0060] (i) polymers with naturally occurring backbones, such as polysaccharides, for example starch, cellulose, dextran or agarose; and
[0061] (ii) polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether;
[0062] b) eluting the adeno-associated virus capsids that incompletely package the genetic material and the adeno-associated virus capsids that fully package the genetic material from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein the conductivity starts at about 0 to about 5 mS / cm and increases by about 0.5 to about 3 mS / cm per step, such as by about 1 to about 2 mS / cm per step, such as by about 1.2 to about 1.5 mS / cm per step, at least up to and including the conductivity at which the adeno-associated virus capsids that incompletely package the genetic material and the adeno-associated virus capsids that fully package the genetic material have been eluted from the chromatography material;
[0063] c) determining, based on the elution curve obtained in step (b), a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not fully package genetic material, and
[0064] d) based on the elution curve obtained in step (b), determining a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that are intactly packaged with genetic material.
[0065] It is shown herein that the currently disclosed pre-screening method is a general approach that addresses the weaknesses of previously applied methods in which differences in ionic capacity, anion exchange ligand density, amount of surface extender, and support material between different batches of chromatography material, as well as feed variability and changes in buffer preparation, make it nearly impossible to predict the amount of conductivity required to achieve baseline separation of intact and empty capsids.
[0066] "Viral particles" are used herein to represent complete infectious viral particles. It includes a core, which contains a viral genome (i.e., viral genome) in the form of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and the core is surrounded by a morphologically defined shell. The shell is called a capsid. The capsid and the encapsulated viral genome together constitute the so-called nucleocapsid. The nucleocapsid of some viruses is surrounded by a lipoprotein double-layer envelope. In the field of bioprocessing, in order to produce viral vectors for various applications such as therapy, the genome of the viral particle is modified to include a genetic insert, which contains the genetic material of interest. The modified viral particles are allowed to infect the host cells in the cell culture and the viral particles are propagated in the host cells, and then the viral particles are purified from the cell culture by any separation and purification means. In this article, the viral particles to be separated from the cell culture by the disclosed method can be alternatively referred to as "target molecules" or "targets". It should be understood that "viral particles" are intended to refer to a type of viral particles and the singular form of the term can cover a large number of separate viral particles. Herein, the term "viral particle" may be used interchangeably with the terms "vector" and "capsid", respectively, as further defined below.
[0067] The term "vector" is used herein to refer to a viral particle, typically a recombinant viral particle, which is intended to be used to achieve gene transfer to modify a specific cell type or tissue. For example, a viral particle can be engineered to provide a vector for expressing a therapeutic gene. Several viral types are currently being studied for delivering genetic material (e.g., genes) to cells to provide transient or permanent transgenic expression. These viral types include adenoviruses, retroviruses (gamma-retroviruses and slow viruses), poxviruses, adeno-associated viruses (AAV), baculoviruses, and herpes simplex viruses. In this article, the term "vector" can be used interchangeably with the terms "viral particle" and "capsid", respectively.
[0068] The term "capsid" refers to the outer shell of a viral particle. The capsid surrounds the core of the viral particle and should generally contain the viral genome. The modified (recombinant) capsid produced in the upstream manufacturing process should contain a complete viral genome, which includes genetic material of interest for one or more applications, such as genetic material of interest for various therapeutic applications. However, due to low packaging efficiency, the assembled capsids do not always contain any genetic material or only encapsidate truncated genetic fragments, which lead to so-called empty capsids and partially filled capsids, respectively. These capsids do not have therapeutic functions, but they compete for binding receptors in cell-mediated processes. This can reduce the overall therapeutic effect and trigger undesirable immune responses. Therefore, tracking these capsids throughout the production process is essential to ensure consistent product quality and appropriate dose response (Xiaotong Fu et al.). In the population of artificially produced viral particles in cell culture, the capsids of up to 20-30% of the viral particles are only partially filled with genetic material. In addition, in up to 98% of artificially produced viral particles, the capsid does not contain any part of the viral genome at all, that is, it is empty. However, typically between 80% and 90% of artificially produced virus particles have empty capsids, and the best cases currently achieve as low as 50% empty capsids.
[0069] In this document, the term "capsid" may be used interchangeably with the terms "vector" and "viral particle", respectively. In the context of the present disclosure, a capsid may or may not contain genetic material.
[0070] The term "genetic material of interest" is intended to refer to genetic material that is considered valuable in the bioprocessing field to be relevant and valuable for production and purification by viral replication, such that it can be used in various applications, such as, but not limited to, therapeutic applications. As a non-limiting example, genetic material of interest can include therapeutically relevant genetic material, such as therapeutically relevant nucleotide sequences.
[0071] The term "capsid completely packaging genetic material" is used herein to refer to a capsid that is correctly produced (by the host cell), or in other words, a capsid that contains a complete viral genome, or in other words, a capsid that contains 100% of its viral genome, or in other words, a capsid that contains a functional viral genome.
[0072] The viral genome includes a genetic insert comprising genetic material of interest, as defined elsewhere herein.
[0073] A capsid containing a complete viral genome may be referred to herein alternatively as a "complete capsid" or a "completely packaged capsid." The terms "complete capsid," "completely packaged capsid," and "capsid that completely packages genetic material" are used interchangeably throughout the text.
[0074] The term "capsid that incompletely packages genetic material" is used herein to refer to a capsid that is incorrectly produced (by the host cell), or in other words, a capsid that does not contain a complete viral genome, or in other words, a capsid that contains less than 100% of its viral genome.
[0075] Capsids that do not fully package genetic material are either partially filled with genetic material or not filled with any genetic material at all.
[0076] The term "capsid that does not fully package genetic material" encompasses the terms "partially filled capsid" and "empty capsid", as defined below.
[0077] "Partially filled capsids" are defined herein as capsids that contain a portion of its viral genome (such as a defective portion of its viral genome), or in other words, capsids that contain a partial viral genome, or in other words, capsids that contain an incomplete viral genome, or in other words, capsids that contain a defective viral genome, or in other words, a capsid that contains a complete viral genome greater than 0% and less than 100%, such as about 1% to about 99%, such as about 5% to about 95%, such as about 10% to about 90%, or such as about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or about 99% of the complete viral genome. Since partially filled capsids are incorrectly produced capsids, it is desirable to separate and remove as many partially filled capsids as possible from the capsid population before the capsid population is used for its intended application (e.g., therapeutic application). In this article, partially filled capsids can be alternatively referred to as "intermediate capsids".
[0078] "Empty capsids" are defined herein as capsids that do not contain any portion of their viral genome, i.e., capsids that contain 0% of their viral genome, or in other words, capsids that are not filled with any genetic material at all. Thus, empty capsids do not contain any genetic material of interest. Therefore, it is desirable (and sometimes necessary, e.g., due to clinical regulations) to separate and remove as many empty capsids as possible from a population of capsids before administering the population of capsids to its intended application (e.g., therapeutic application).
[0079] Before administering a population of viral particles for its intended application (e.g., therapeutic application), it is desirable (and sometimes even required, e.g., due to clinical regulations) to enrich for intact capsids, i.e., to increase the percentage of intact capsids at the expense of the percentage of partially filled capsids and empty capsids.
[0080] The percentage of complete capsids and empty capsids in the capsid population can be estimated or analyzed by several methods known in the art. Some of these methods are briefly described below:
[0081] 1: The A260:280 in the chromatogram will give an estimate of the percentage of intact capsids present in the peak (a ratio of 1-1.5 indicates an abundance of intact capsids, a ratio of 0.5-0.7 contains mostly empty capsids).
[0082] 2. qPCR:ELISA ratio. qPCR quantifies viral genomes, and ELISA quantifies total viral particles. The ratio of the two assays with variation is less accurate and will be inconclusive. Orthogonal analysis is required for confirmation (see 3, 4, or 5 below).
[0083] 3. Analytical anion exchange separation of intact and empty capsids (A260:280 ratio and peak area to calculate percentages). Precision depends on peak definition.
[0084] 4. Analytical ultracentrifugation (AUC). Detects and quantifies particles of different densities (corresponding to complete capsids, partially filled capsids and empty capsids). This is currently known as the "gold standard" in the field. However, ultracentrifugation is not scalable and is therefore not suitable for the analysis of large quantities of capsids.
[0085] 5. Transmission electron microscopy (TEM). Image analysis counts particles (complete capsids, partially filled capsids and empty capsids). Artifacts may be introduced from sample preparation.
[0086] Some methods for estimating or analyzing the percentage of intact and empty capsids in a capsid population are described in more detail in Xiaotong Fu et al., which is hereby incorporated herein by reference.
[0087] It should be understood that the term "liquid sample" as used herein encompasses any type of sample obtainable from a cell culture, or any type of sample obtainable from a fluid derived from a cell culture, which fluid is at least partially purified by any separation and purification means.
[0088] The term "separation matrix" is used herein to represent a material comprising a support to which one or more ligands comprising functional groups have been coupled. The functional group of the ligand is combined with a compound also referred to herein as an analyte, which is to be separated from a liquid sample and / or to be separated from other compounds present in the liquid sample. The separation matrix may also include a compound coupling the ligand to the support. The terms "joint", "extending agent" and "surface extending agent" may be used to describe such compounds, as further described below. The term "resin" is sometimes used for separation matrices in the art. The terms "chromatographic material" and "chromatographic matrix" are used herein to represent the type of separation matrix.
[0089] The term "surface" herein refers to all external surfaces and in the case of porous supports includes the outer surface as well as the pore surface.
[0090] In this article, the term "strong anion exchange chromatography material" is intended to refer to a chromatography material comprising a ligand comprising a quaternized amine group. A quaternary amine group is a strong anion exchange group, which is always positively charged regardless of the pH to which it is subjected. For chromatography materials based on the type of DEAE, the quaternization degree of the amine group can vary between the amine groups contained in the chromatography material. The quaternization degree of the amine groups from about 12% to about 100% in the chromatography material is generally considered to produce a chromatography material that behaves like a strong or at least partially strong anion exchange chromatography material, because these at least 12% groups of all amine groups are always charged. Compared with quaternized amine groups, almost all other ion exchange groups are weak, i.e., their charge varies from fully charged to uncharged in a reasonable range of pH used (such as pH 2-11) and has a neutral charge (same amount of + and - charges) at pI.
[0091] Capto Q (Cytiva, Sweden) is a non-limiting example of a strong anion exchange chromatography material with about 100% quaternized amine groups. Capto DEAE (Cytiva, Sweden) is a non-limiting example of a strong or partially strong anion exchange chromatography material with a degree of quaternization of the amine groups of about 15%.
[0092] The separation matrix can be contained in any type of separation device, as further defined elsewhere herein. As a non-limiting example, the chromatographic material can be loaded in a chromatographic column, and the liquid sample is then added to the chromatographic material contained in the chromatographic column. As another example, for the pre-screening method of the present invention, the chromatographic material can be provided in a porous format, for example, in the form of a porous plate with a hole containing the chromatographic material (e.g., PreDictor Capto Q plate, Cytiva, Sweden).
[0093] In this context, a "ligand" is a molecule with a known or unknown affinity for a given analyte, and includes any functional group or capture agent immobilized on its surface, while an "analyte" includes any specific binding partner of the ligand. The term "ligand" may be used interchangeably herein with the terms "specific binding molecule," "specific binding partner," "capture molecule," and "capture agent." In this article, the molecule in the liquid sample that interacts with the ligand is referred to as an "analyte." The analyte of interest according to the present disclosure is an adeno-associated virus capsid, more particularly an adeno-associated virus capsid that completely packages genetic material or incompletely packages genetic material. Therefore, the terms "analyte," "adeno-associated virus capsid," and "capsid" may be used interchangeably herein.
[0094] In the method disclosed herein for separating the capsid of complete package from the capsid of incomplete package, the chromatographic material used comprises a joint connecting the ligand to the support, that is, the coupling of the ligand to the support is provided by introducing a joint between the support and the ligand. The coupling can be carried out according to any conventional covalent coupling method, such as by using epichlorohydrin; epibromohydrin; allyl-glycidyl ether; diepoxides such as butanediol diglycidyl ether; halogen-substituted aliphatic substances such as dichloropropanol; and divinyl sulfone. Other non-limiting examples of suitable joints are: polyethylene glycol (PEG) with 2-6 carbon atoms, carbohydrates with 3-6 carbon atoms, and polyols with 3-6 carbon atoms. These methods are well known in the art and are easily implemented by technicians.
[0095] The ligand is coupled to the support via a longer linker molecule (also referred to as a "surface extender" or simply "extender"). Extenders are well known in the art and are typically used to spatially increase the distance between the ligand and the support. Extenders sometimes represent tentacles or flexible arms. For a more detailed description of possible chemical structures, see, for example, US 6,428,707, which is hereby included in this article by reference. In short, the extender can be in the form of a polymer such as a homopolymer or a copolymer. The hydrophilic polymer extender can be of synthetic origin, i.e., having a synthetic backbone, or of biological origin, i.e., a biopolymer with a naturally occurring backbone. Typical synthetic polymers are polyvinyl alcohol, polyacrylamide and polymethacrylamide, polyvinyl ethers, etc. Typical biopolymers are polysaccharides, such as starch, cellulose, dextran, agarose. Extenders can be linear and nonlinear (branched) polymers, such as brush polymers, which are long linear structures with functional appendages along their length. The results described in the Examples herein surprisingly show that a chromatography material comprising a surface extending agent provides improved separation of intact AAV capsids from empty AAV capsids compared to the same chromatography material not comprising a surface extending agent.
[0096] The term "eluent" is used in its conventional sense in the art, ie, a buffer having a suitable pH and / or ionic strength to release one or more compounds from a separation matrix.
[0097] The term "eluate" is used in its conventional meaning in the art, ie, the portion of a liquid sample that elutes from a chromatography column after loading the liquid sample onto the chromatography column.
[0098] As mentioned above, in the method for determining elution conditions suitable for separating intact packaged capsids from incomplete packaged capsids, the liquid sample added to the chromatographic material in step (a) comprises a purity of at least 90%, such as 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, and a concentration of at least 10 12 , such as 10 13 , 10 14 or 10 15 Adeno-associated virus capsids / ml of adeno-associated virus capsids, wherein at least 5%, such as 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70% or 80% of the adeno-associated virus capsids are complete adeno-associated virus capsids that package genetic material. With regard to the purity of adeno-associated capsids in a liquid sample, a purity of at least 90%, such as up to 99%, is intended to mean that at least 90%, such as up to 99%, of the biological material in the liquid sample is represented by adeno-associated capsids (including complete capsids, empty capsids and partially filled capsids), while the remaining up to 10%, such as 1%, is represented by host cell proteins and DNA.
[0099] As described in step (b) of the pre-screening method above, the step gradient elution is designed in the form of a stepwise slowly increasing conductivity starting from about 0 to about 5 mS / cm, such as about 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 or 5.0 mS / cm. The step gradient is increased by about 0.5-3 mS / cm increments per step, such as about 1 to about 2 mS / cm per step, such as about 1.2 to about 1.5 mS / cm per step, or about 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 or 3.0 mS / cm per step, at least up to and including the conductivity at which capsids with incomplete genetic material packaging and capsids with complete genetic material packaging have eluted from the chromatography material to identify the conductivity values required to elute empty capsids and complete capsids, respectively. It will be appreciated that the conductivity step gradient may optionally be increased to a conductivity above that at which both empty and intact capsids have been eluted.
[0100] As described in steps (c) and (d) of the above pre-screening method, the first value and the second value of the conductivity or conductivity-related parameter are determined based on the elution curve obtained in step (b). The elution curve can be in the form of a chromatogram or a table or graph containing elution-related values.
[0101] The term "conductivity-related parameter" as used herein means a parameter that affects the conductivity of a solution. The conductivity-related parameter may, for example, be directly correlated or negatively correlated with the conductivity. Non-limiting examples of conductivity-related parameters that may be relevant in this context are salt concentration and pH, and the presence / concentration of a compound that improves the separation between capsids that fully package the genetic material and capsids that incompletely package the genetic material. The compound that improves the separation may, for example, be selected from carbohydrates, divalent metal ions, and detergents, as described in further detail below.
[0102] The first value of the conductivity or conductivity-related parameter determined should be suitable for eluting adeno-associated virus capsids that do not completely package genetic material, and the second value of the conductivity or conductivity-related parameter determined should be suitable for eluting adeno-associated virus capsids that completely package genetic material. In a pre-screening method in which empty capsids are eluted before complete capsids, the first value of conductivity is typically determined as the conductivity value applied when eluting the first peak containing empty capsids and / or complete capsids. If the empty capsids do not bind to the column, but eventually enter the flow-through, the first value of conductivity will be the same as the baseline conductivity value, i.e., the conductivity before the step gradient of conductivity is applied. Therefore, in some cases, the first value of conductivity can be determined to be as low as 0 mS / cm.
[0103] In a pre-screening method where empty capsids elute before intact capsids, the second value of conductivity is typically determined as a conductivity value that is equal to or higher than the conductivity value that applies when the last peak containing empty capsids and / or intact capsids elutes. For example, if the last peak elutes at a conductivity value of 5 mS / cm, the second value of conductivity is determined to be ≥ 5 mS / cm.
[0104] The elution buffer used in the step (b) of the pre-screening method may contain salt. The step gradient of increasing conductivity in the step (b) of the pre-screening method may be a step gradient of increasing salt concentration. In this context, the conductivity-related parameter mentioned in the steps (c) and (d) of the pre-screening method may be salt concentration. Salt may be a lyophilic salt. Salts in aqueous solvents are defined as lyophilic (order formation) if they promote the stability and structure of water-water interactions. In contrast, chaotropic (disorder formation) salts have the opposite effect, destroying water structure, increasing the solubility of non-polar solvent particles, and making solute aggregates unstable. Lyophiles cause water molecules to interact favorably, which in effect stabilizes intramolecular interactions in macromolecules such as proteins (Moelbert S et al.). A grade may be established, for example, by reference to the Hofmeister series or the lyotropic ion series, which is an ion classification (Hyde A et al.) in the order of their ability to salt out or dissolve in proteins.
[0105] More specifically, the salt may comprise (i) a compound selected from CO 3 2- 、SO 4 2- , S 2 O 3 2- , H 2 PO 4 - , HPO 4 2- , acetate - , Citrate - and Cl - anion, and (ii) selected from NH 4 + , K + 、Na + and Li +In a preferred embodiment, the salt is sodium acetate (NaOAc). Non-limiting examples of suitable concentrations of NaOAc include about 5 mM to about 500 mM, such as about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mM. However, it should be understood that other salts composed of combinations of anions listed under (i) and cations listed under (ii) may alternatively be used to elute the capsid. Non-limiting examples of such other salts are NaCl, LiCl, KCl or other equivalent metal salts suitable for salt elution, as well known in the art. Non-limiting examples of suitable concentrations of NaCl include about 5 mM to about 2 M, e.g., about 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, or 2000 mM.
[0106] Step (b) of the pre-screening method may comprise adding a volume of elution buffer corresponding to about 1 to about 10 volumes, e.g., about 2 to about 8 volumes, e.g., about 5 volumes, or about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 volumes of chromatography material per step of the step gradient.
[0107] The above pre-screening method is followed by a two-step elution method designed based on the information provided by the elution curve (e.g., chromatogram) obtained in the pre-screening method. More specifically, Figure 2 As described, the present disclosure further provides a method for separating completely packaged adeno-associated virus capsids from incompletely packaged adeno-associated virus capsids, comprising performing steps (a)-(d) of the pre-screening method described in detail above, the method further comprising the following steps (e)-(g):
[0108] e. will contain a purity of at least 90% and a concentration of at least 10 12 a liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml of adeno-associated virus capsids is added to a chromatographic material as defined in step (a), wherein at least 5%, such as 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70% or 80% of the adeno-associated virus capsids are adeno-associated virus capsids that are intact and packaged with genetic material, and the liquid sample is derived from the cell culture harvest from which the liquid sample of step (a) is derived;
[0109] f. eluting adeno-associated viral capsids that are incompletely packaged with genetic material by applying an elution buffer having a first value of conductivity or a conductivity-related parameter as determined in step (c); and
[0110] g. eluting the adeno-associated virus capsids intactly packaged with genetic material by applying an elution buffer having a second value of conductivity or a conductivity-related parameter as determined in step (d);
[0111] in
[0112] (i) the duration of step (f) is at least 3 times, for example 4 times, the duration of step (g), and / or
[0113] (ii) the method comprises a step (f') between step (f) and step (g), wherein step (f') comprises applying a further step elution and / or an increasing conductivity gradient between a first value and a second value of the conductivity or a conductivity-related parameter, and the duration of steps (f) and (f') is at least 3 times, for example 4 times, the duration of step (g).
[0114] In order that the elution conditions determined in the prescreening method are indeed also applicable to the liquid sample added in step (e), the liquid sample added in step (e) should originate from the same cell culture harvest as the liquid sample of step (a) of the prescreening method.
[0115] The purpose of steps (f) and (g) of the method disclosed above is to obtain intact packaged capsids with as high a purity as possible. It is readily understood by those skilled in the art that this can be achieved by applying a variety of different separation conditions. Non-limiting examples of separation conditions for obtaining intact packaged capsids with as high a purity as possible include separation conditions that allow incompletely packaged capsids to bind to the chromatographic material while:
[0116] (i) allowing the intact packaged capsid to substantially flow through the chromatographic material (i.e., the intact packaged capsid does not substantially bind to the chromatographic material), or
[0117] (ii) allowing the fully packed capsids to bind to the chromatography material and then eluting them from the chromatography material. It should be understood that in the bind-elute process described in item (ii), the fully packed capsids can be eluted from the chromatography material before or after the incomplete packed capsids, depending on the separation conditions applied.
[0118] As mentioned above, there are small differences between fully packaged capsids and incompletely packaged capsids in several parameters relevant to purification (e.g., their isoelectric points). This often results in (at least partial) co-elution of fully packaged capsids and incompletely packaged capsids. Therefore, in practice, the adeno-associated virus capsids eluted in step (b) of the method disclosed above will not be completely separated into complete capsids, empty capsids and partially filled capsids. However, there is an eluate fraction containing a significantly higher percentage of complete capsids than in the liquid sample added to the chromatographic material in step (e). More specifically, the adeno-associated virus capsid eluted in step (g), i.e., the adeno-associated virus capsid that completely packages the genetic material, can be eluted into an eluate fraction, and the combined eluate fraction contains at least 50%, such as 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% of the adeno-associated virus capsid of the liquid sample added in step (e), wherein at least 60%, such as 65%, 70%, 75%, 80%, 85% or 90% of the adeno-associated virus capsid completely packages the genetic material. A non-limiting example of the recovery and purification of complete capsids achieved by the method of the present disclosure is to recover at least 50% of the capsids of the liquid sample added in step (e), wherein at least 60% are complete capsids, such as recovering at least 70% of the capsids of the liquid sample added in step (a), wherein at least 80% are complete capsids. In Example 1, described further below, results show that at least 80% of the viral genome was recovered from the harvest, of which at least 70% was intact capsids.
[0119] It has been found to be advantageous to carry out step (f) for a duration that is at least 3 times, for example 4 times, 5 times or more, longer than the duration of step (g). Without wishing to be bound by theory, it is believed that a relatively longer duration of step (f) is beneficial, or even critical, for the presence of substantially all or nearly all empty capsids in the eluted liquid sample.
[0120] As an alternative to performing step (f) for a duration that is at least 3 times the duration of step (g), the method may comprise applying a further step (f') between step (f) and step (g), wherein the duration of steps (f) and (f') is at least 3 times, such as 4 times, 5 times or more, the duration of step (g). Step (f') may for example comprise:
[0121] (i) an elution step performed at a value of conductivity or a conductivity-related parameter between a first value and a second value of conductivity or a conductivity-related parameter,
[0122] (ii) a linear gradient of increasing conductivity between a first value and a second value of conductivity or a conductivity-related parameter, or
[0123] (iii) A combination of (i) and (ii).
[0124] The difference in duration between step (f) and step (g) can be achieved by adding in step (f) a volume of elution buffer that is at least 3 times, e.g., 4 times or more, of the volume of elution buffer added in step (g). As a non-limiting example, in step (f) a volume of elution buffer corresponding to about 3 to about 30 volumes, e.g., about 6 to about 24 volumes, e.g., about 15 volumes or about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 volumes of chromatography material is added, whereas in step (g) an elution buffer corresponding to a volume of about 1 to about 10 volumes, e.g., about 2 to about 8 volumes, e.g., about 5 volumes or about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 volumes of chromatography material is added. Similarly, if the method includes step (f'), the difference in duration between steps (f) + (f') and step (g) may be achieved by adding in steps (f) + (f') a volume of elution buffer that is at least 3 times, for example 4 times or more, the volume of elution buffer added in step (g).
[0125] Used in steps (b), (f), optionally (f') and (g) of the above method to separate capsids (and Figure 2 The elution buffer (described in the method) may contain salt. The step gradient of increasing conductivity as mentioned in step (b) of the method may be a step gradient of increasing salt concentration. In this case, the conductivity-related parameter as mentioned in steps (c), (f) and (g) of the method may be salt concentration. The salt may be a lyophilic salt, as defined elsewhere herein.
[0126] More specifically, the salt may comprise (i) a compound selected from CO 3 2- 、SO 4 2- , S 2 O 3 2- , H 2 PO 4 - , HPO 4 2- , acetate - , Citrate - and Cl - anion, and (ii) selected from NH 4 + , K + 、Na + and Li +In a currently preferred embodiment, the salt is sodium acetate. However, it should be understood that other salts consisting of a combination of anions listed under (i) and cations listed under (ii) may alternatively be used to elute the capsid.
[0127] Step (b) of the method may comprise adding a volume of elution buffer corresponding to about 1 to about 10 volumes, such as about 2 to about 8 volumes, for example about 5 volumes or about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 volumes of chromatography material per step of the step gradient.
[0128] like Figure 3 As described, the present disclosure further provides a method for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method comprising:
[0129] (I) will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml of adeno-associated virus capsids is added to a strong or partially strong anion exchange chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids, wherein at least 5% of the adeno-associated virus capsids are intact adeno-associated virus capsids that package genetic material,
[0130] wherein the chromatographic material comprises a surface extending agent that attaches the ligand to the support, wherein the surface extending agent is a polymer, wherein the polymer is selected from:
[0131] (i) polymers having a naturally occurring backbone, such as a polysaccharide, for example starch, cellulose, dextran or agarose, and
[0132] (ii) polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether;
[0133] (II) eluting adeno-associated virus capsids that incompletely package genetic material by applying an elution buffer having a predetermined first value of conductivity or a conductivity-related parameter;
[0134] (III) eluting the intact adeno-associated virus capsids packaging the genetic material by applying an elution buffer having a predetermined second value of conductivity or a conductivity-related parameter;
[0135] The predetermined first and second values of conductivity or a conductivity-related parameter are present in a sample having a purity of at least 90% and a concentration of at least 10 12adeno-associated virus capsids / ml, wherein at least 5%, such as 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80% of the adeno-associated virus capsids are intact adeno-associated virus capsids that package genetic material, and the liquid sample is derived from the cell culture harvest from which the liquid sample of step (I) is derived;
[0136] in
[0137] (i) the duration of step (II) is at least 3 times, such as 4 times, 5 times or more, longer than the duration of step (III), and / or
[0138] (ii) the method comprises a step (II') between step (II) and step (III), wherein step (II') comprises applying a step elution and / or an increasing conductivity gradient between a first value and a second value of conductivity or a conductivity-related parameter, and the duration of steps (II) and (II') is at least 3 times, for example 4 times, 5 times or more, the duration of step (III).
[0139] like Figure 3 The method described in Figure 2 Same method as described in Figure 3 The method does not include the step of determining a first value and a second value of the conductivity or conductivity-related parameter. Instead, Figure 3 The method uses predetermined first and second values of conductivity or a conductivity-related parameter. Optionally, the first and second values of conductivity or a conductivity-related parameter may have been predetermined (i.e., may have been determined in advance) by performing steps (a)-(d) of the pre-screening method disclosed herein as described in further detail above.
[0140] It should be understood that the above Figure 2 The embodiments and details described in steps (e), (f), optionally (f') and (g) of the method can also be applied to Figure 3 The method comprises steps (I), (II), optionally (II') and (III).
[0141] As described above, in the above detailed description and in Figure 1 , Figure 2 and Figure 3 The chromatographic material used in any of the methods disclosed herein as described in , respectively, comprises a strong or partially strong anion exchange chromatographic material comprising a support, a ligand for binding to an adeno-associated virus capsid, and a surface extender.
[0142] The strong anion exchange chromatography material can be defined by the following formula I:
[0143]
[0144] Where R 1 is selected from C1-C3 alkyl, and R 2 and R 3 Independently selected from C1-C3 alkyl, CH2OH and CH2CHOHCH3.
[0145] As a non-limiting example, R 1 , R 2 and R 3 Each is CH3.
[0146] Currently available are chromatographic materials comprising a ligand defined by formula I, wherein R 1 , R 2 and R 3 each is CH3; for example, a chromatography material available under the name Capto Q provided by Cytiva of Sweden (www.cytivalifesciences.com). CaptoQ also contains dextran as a surface extender and is a chromatography medium used in high-resolution polishing steps in industrial purification processes, for example for the purification of monoclonal antibodies.
[0147] According to another non-limiting example, R 1 and R 2 is ethyl, and R 3 It is methyl.
[0148] According to yet another non-limiting example, R 1 and R 2 is methyl, and R 3 It is CH2CHOHCH3.
[0149] The density of the ligand defined by formula I may be from about 60 to about 500 μmol, such as from about 160 to about 350 μmol, such as from about 160 to about 220 μmol ligand per ml of strong anion exchange chromatography material.
[0150] Alternatively, the strong or partially strong anion exchange chromatography material may be defined by the following formula II:
[0151]
[0152] in:
[0153] m is an integer from 1 to 3;
[0154] R 1 and R 2 Independently selected from C1-C3 alkyl; R 3 and R 4is independently selected from C1-C3 alkyl and CH2CHOHCH3; and R 5 is selected from hydrogen, C1-C3 alkyl and CH2CHOHCH3;
[0155] Provided that if m is 1, the strong or partially strong anion exchange chromatography material is defined by the following formula III:
[0156]
[0157] wherein n is an integer from 0 to 3;
[0158] The premise is that if n is 0, then R 3 and R 4 are independently selected from C1-C3 alkyl, and R 5 It is hydrogen or CH2CHOHCH3.
[0159] As a non-limiting example, the ligand is defined by Formula III and comprises a combination of two or more of the following structures (i)-(iv):
[0160] (i) n is 0; R 3 and R 4 is ethyl; and R 5 is hydrogen or CH2CHOHCH3;
[0161] (ii) n is 1; R 1 , R 2 , R 3 , R 4 is ethyl; and R 5 is hydrogen or CH2CHOHCH3;
[0162] (iii) n is 2; R 1 and R 2 Each is ethyl; R 3 and R 4 is ethyl; and R 5 is hydrogen or CH2CHOHCH3;
[0163] (iv) n is 3; R 1 and R 2 Each is ethyl; R 3 and R 4 is ethyl; and R 5 It is hydrogen or CH2CHOHCH3.
[0164] A currently available chromatography material comprising a ligand defined by formula III and comprising a combination of structures (i)-(iv) mentioned above is a chromatography resin called Capto DEAE (Cytiva, Sweden). Capto DEAE also contains dextran as a surface extender and is a chromatography medium used in high-resolution polishing steps in industrial purification processes, for example for the purification of monoclonal antibodies.
[0165] According to another non-limiting example, the ligand is defined by Formula III, wherein m is 1; n is 1, 2 or 3; R 1 , R 2 , R 3 and R 4 Each is methyl; and R 5 For hydrogen.
[0166] According to yet another non-limiting example, the ligand is defined by Formula III, wherein m is 1; n is 1, 2 or 3; R 1 , R 2 , R 3 and R 4 Each is methyl; and R 5 It is CH2CHOHCH3.
[0167] According to another non-limiting example, the ligand is defined by Formula III, wherein m is 1 and the ligand comprises a combination of two or more of the following structures (i)-(iv):
[0168] (i) n is 0; R3 and R4 are methyl; R5 is hydrogen or CH2CHOHCH3;
[0169] (ii) n is 1; R1, R2, R3 and R4 are methyl; R5 is hydrogen or CH2CHOHCH3;
[0170] (iii) n is 2; R1 and R2 are each methyl; R3 and R4 are methyl; R5 is hydrogen or CH2CHOHCH3;
[0171] (iv) n is 3; R1 and R2 are each methyl; R3 and R4 are methyl; R5 is hydrogen or CH2CHOHCH3.
[0172] The density of the ligand defined by Formula II or Formula III may be about 60 to about 500 μmol, such as about 160 to about 350 μmol, such as about 290 to about 350 μmol ligand per ml of strong anion exchange chromatography material.
[0173] As described above, the chromatographic material comprises a surface extending agent that links the ligand to the support, wherein the surface extending agent is a polymer, wherein the polymer is selected from:
[0174] (i) polymers with naturally occurring backbones, such as polysaccharides, such as starch, cellulose, dextran or agarose; and
[0175] (ii) Polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether.
[0176] As a non-limiting example, the surface extension agent is dextran. Dextran can have a molecular weight of about 10 to about 2000 kDa, such as about 10, 40, 70, 250, 750 or 2000 kDa, such as 40 kDa. The density of dextran can be about 5 to about 30 mg dextran / ml chromatographic material. It should be understood that the amount of dextran fixed on the chromatographic material can vary, for example, depending on the molecular weight of the fixed dextran. Usually, increasing the molecular weight of dextran needs to reduce the dosage.
[0177] The pre-screening method disclosed above ( Figure 1 ) and separation methods ( Figure 2 ), and Figure 2 The separation method of steps (e), (f), (f'), (g) and Figure 3 Steps (I), (II), (II') and (III) of the separation method can include applying a buffer having a pH of about 6.0 to about 10.5, such as about 7.0 to about 10.0, such as about 7.5 to about 9.5, or about 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 or 10.5. According to non-limiting examples, as described in Examples 1-3 below, a pH of about 7.0, 9.0 or 9.5 can be applied to the chromatographic material comprising the ligand defined by Formula I. In addition, as described in Example 1 below, a pH of about 9.0 can be applied to the chromatographic material comprising the ligand defined by Formula II or Formula III.
[0178] The buffer is suitably selected from buffers generally recommended for anion exchange chromatography and may, for example, comprise tris(hydroxymethyl)amino-methane (i.e. Tris), 1,3-bis(tris(hydroxymethyl)methylamino)propane (i.e. Bis-Tris propane), triethanolamine, N-methyldiethanolamine, diethanolamine, 1,3-diaminopropane or ethanolamine. Those skilled in the art will be able to select a suitable concentration for any of the buffers listed above.
[0179] In the pre-screening method disclosed above, step (b) may comprise applying a buffer, optionally one of the buffers mentioned above, wherein the buffer comprises a compound that improves the separation between capsids that fully package the genetic material and capsids that incompletely package the genetic material. If so, in the separation method ( Figure 2), in steps (b), (f), (f') and (g), the buffer should contain the same compound. Similarly, steps (II), (II') and (III) should include applying the same buffer as the buffer applied when the first value and the second value of the conductivity or conductivity-related parameter are predetermined, optionally one of the above-mentioned buffers, which contains the same compound that improves the separation between the completely packaged capsid and the incompletely packaged capsid. The compound may be present or absent in the buffer applied in steps (a), (e) and (I) of the method disclosed above, respectively. Without being bound by theory, such a compound can improve the separation, for example, by affecting the interaction between the capsid and the ligand or the interaction between the capsid and the capsid. The compound that improves the separation can, for example, be selected from carbohydrates, divalent metal ions and detergents.
[0180] When the separation improving compound is a carbohydrate, it may for example be selected from sucrose, sorbitol and polysaccharides.
[0181] When the separation-improving compound is a divalent metal ion, it may be selected, for example, from Mg 2+ , Fe 2+ and Mn 2+ The metal ions may be present in the form of a salt, optionally in combination with, for example, chloride or sulfate ions. A non-limiting example of a suitable metal salt for inclusion in the buffer of step (b) is MgCl 2 MgCl 2 Non-limiting examples of suitable concentrations include about 0.5 to about 30 mM MgCl 2 , such as about 1 to about 20 mM, such as about 2 to about 10 mM, or about 0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25 or 30 mM MgCl 2 .
[0182] When the separation-improving compound is a detergent, it can be selected, for example, from poloxamers (such as poloxamer 188 or Pluronic TM F68) and polysorbates (such as Tween 20 or Tween 80).
[0183] As described in Example 1 below, non-limiting examples of suitable buffer systems for use in the methods disclosed above include buffer A and buffer B, both containing 20 mM Bis-Tris propane (BTP) pH 9.0 and 2 mM MgCl2, and buffer B additionally containing 250 mM sodium acetate (NaOAc) as an elution salt. Buffer A is used in steps (a), (e) and (i), respectively. A step gradient of buffer B is used in step (b) of the pre-screening method. The first value and the second value of the conductivity or conductivity-related parameter are determined by Figure 2 In steps (f) and (g) of the method, or Figure 3 The steps (II) and (III) of the method are respectively achieved by using a mixture of buffer A and buffer B in appropriate proportions.
[0184] As described in Example 2 below, another non-limiting example of a suitable buffer system for use in the methods disclosed above includes buffer A and buffer B, both containing 20 mM Bis-Tris propane (BTP) pH 7.0, 1% sucrose, and 0.1% Pluronic, and buffer B additionally comprising 20 mM MgCl 2 .
[0185] As described in Example 3 below, another non-limiting example of a suitable buffer system for use in the methods disclosed above includes buffer A and buffer B, both of which contain 20 mM Bis-Tris propane (BTP), 18 mM MgCl2, 1% sucrose and 0.1% Pluronic at a pH of 7.0 or 9.5, respectively, and buffer B additionally contains 400 mM NaCl.
[0186] The chromatographic material used in the method disclosed herein comprises a support for the ligand to be coupled thereto. The support can be made of an organic or inorganic material and can be porous or non-porous. In one embodiment, the support is prepared by a natural polymer, such as a cross-linked carbohydrate material, for example agarose, agar, cellulose, dextran, chitosan, konjac, carrageenan, gellan gum, alginate, pectin, starch, etc. The natural polymer support is readily prepared and optionally cross-linked according to standard methods, such as reverse suspension gelation (S Hjerten: Biochim Biophys Acta 79 (2), 393-398 (1964). In a particularly advantageous embodiment, the support is a relatively rigid but porous agarose, which is prepared by methods that enhance its flow properties, see, for example, US 6,602,990 (Berg). In an alternative embodiment, the support is prepared from a synthetic polymer or copolymer, such as a cross-linked synthetic polymer, for example styrene or styrene derivatives, divinylbenzene, acrylamide, acrylate, methacrylate, vinyl ester, vinyl amide, etc. Such synthetic polymers are readily prepared and optionally cross-linked according to standard methods, see, for example, "Styrene based polymer supports developed by suspension polymerization" (R Arshady: Chimica e L'Industria 70(9), 70-75 (1988)). Natural or synthetic polymer supports can also be obtained from commercial sources, such as Cytiva of Sweden, for example in the form of porous particles. In yet another alternative embodiment, the support is prepared from an inorganic polymer such as silica. Inorganic porous and non-porous supports are well known in the art and are readily prepared according to standard methods.
[0187] The support for the chromatographic material may be in the form of particles, such as substantially spherical, elongated or irregularly shaped particles.
[0188] When the chromatographic material is in the form of particles, the particles may be particles having uniform porosity and being at least partially permeable to the adeno-associated virus capsid.
[0189] As used herein, the term "uniform porosity" is intended to mean that a particle having uniform porosity has uniform porosity throughout its entire structure or volume, such that each particle is at least partially permeable to adeno-associated viral capsids throughout its entire structure or volume. In other words, a particle having uniform porosity has a porosity that allows adeno-associated viral capsids to diffuse completely or at least partially through its pores throughout the entire structure or volume of the particle.
[0190] The diameter of the adeno-associated virus is about 20-25 nm. Since the capsid is the outer shell of the virus particle, and since the adeno-associated virus does not have a lipoprotein bilayer envelope surrounding the capsid, the size of the adeno-associated virus capsid is about 20-25 nm in diameter.
[0191] Thus, when the chromatographic material is in the form of particles having uniform porosity and at least partially permeable to adeno-associated viral capsids, each particle may suitably contain pores having a diameter > 25 nm, i.e., larger than the diameter of the adeno-associated viral capsids to be separated, so that the capsids can diffuse throughout the particle. It should be understood that for the specific purposes of the present disclosure, i.e., for the separation of adeno-associated viral capsids, a diameter > 25 nm may be a diameter of any size > 25 nm, including but not limited to 30, 50, 75, 100, 150 or 200 nm.
[0192] In addition, it should be understood that a particle having uniform porosity throughout its entire structure or volume may still contain pores of different sizes: pores that are large enough to easily allow the capsid to diffuse within the particle and pores that are small enough not to allow the capsid to diffuse. This pore size diversity can be measured by the diffusion coefficient of molecules with a well-defined molecular weight and hydrodynamic size. As a non-limiting example, a dextran with a molecular weight of 140-225 kDa or a hydrodynamic diameter of 20-25 nm (i.e., a diameter of the same size as an adeno-associated virus capsid) can be used to evaluate the degree of diffusion of an adeno-associated virus capsid within the pores of the particle.
[0193] The chromatographic materials Capto Q and Capto DEAE advantageously used in Examples 1-3 herein comprise a support in the form of essentially spherical particles or beads having a diameter of approximately 90 μm. This type of particle is a non-limiting example of a particle having uniform porosity (i.e., throughout its entire structure or volume) and at least partially permeable to adeno-associated virus capsids (i.e., throughout its entire structure or volume).
[0194] The suitable particle size of the chromatographic material used in the method of the present disclosure can be in the range of 5-500 μm in diameter, such as 10-100 μm, for example 30-90 μm. In the case of substantially spherical particles, the average particle size can be in the range of 5-1000 μm, such as 10-500 μm. In a specific embodiment, the average particle size is in the range of 10-200 μm. Those skilled in the art can easily select suitable particle size and porosity according to the method to be used. For example, for large-scale methods, for economic reasons, more porous but rigid supports can be preferred to allow large volumes of processing, especially for capture steps. In chromatography, process parameters such as the size and shape of the column will affect the selection. In an expanded bed method, the matrix usually contains a high-density filler, preferably a stainless steel filler. For other methods, other criteria may affect the properties of the matrix.
[0195] The chromatographic material may be dry, such as dry particles, which are soaked in a liquid to maintain their original form when used. For example, such a dry chromatographic material may comprise dry agarose particles.
[0196] The chromatographic material can be in the form of magnetic particles, i.e., magnetically adsorbed beads. The term "magnetic particles" is defined in the text as particles that can be attracted by a magnetic field. At the same time, the magnetic particles used in the methods disclosed herein should not aggregate in the absence of a magnetic field. In other words, the magnetic particles should behave like superparamagnetic particles. The particles may have any symmetrical shape, such as spherical or cubic, or any asymmetric shape. Spherical magnetic particles are generally referred to as magnetic beads. It should be understood that the terms "magnetic particles", "magnetic beads", "Mag particles", "Mag beads", "mag particles" and "mag beads" are used interchangeably in the text without limiting the scope to magnetic particles having a spherical shape. It is known in the art to separate biomolecules using magnetically adsorbed beads. Magnetic particles suitable for use in the methods disclosed herein have been described in WO2018122089, which is incorporated herein by reference in its entirety. A non-limiting example of a magnetic particle that can be used in the methods disclosed herein is Mag Sepharose TM PrismA (Cytiva, Sweden).
[0197] The support for the chromatographic material may alternatively take any other shape conventionally used in separations, such as a monolith, a filter or membrane, a capillary, a chip, a nanofiber, a surface, and the like.
[0198] When the support for the chromatographic material comprises a monolith, for the purpose of separating adeno-associated virus capsids, suitable pore diameters in the monolith range from a minimum pore diameter of greater than 25 nm (i.e., greater than the diameter of the capsids to be separated) to a maximum pore diameter of up to about 5 μm, such as about 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 μm.
[0199] When the support of the chromatographic material comprises nanofibers, such nanofibers may for example comprise electrospun polymer nanofibers. When in use, such nanofibers form a stationary phase comprising a plurality of pores through which the mobile phase can permeate.
[0200] The support of chromatographic material can include membrane structure, such as single membrane, a pile of membrane or filter.Membrane can be adsorptive membrane.When the support of chromatographic material includes membrane structure, for the purpose of separating adeno-associated virus capsid, the suitable pore diameter in membrane structure is greater than 25nm minimum pore diameter (that is, greater than the diameter of capsid to be separated) to the maximum pore diameter of up to about 5 μm in the range of, such as about 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 μm.When chromatographic material includes membrane structure, such membrane structure can, for example, include the nonwoven web of polymer nanofiber.
[0201] Non-limiting examples of suitable polymers may be selected from polysulfone, polyamide, nylon, polyacrylic acid, polymethacrylic acid, polyacrylonitrile, polystyrene and polyethylene oxide, and mixtures thereof.
[0202] Alternatively, the polymer can be a cellulose polymer, such as selected from cellulose and partial derivatives of cellulose, in particular cellulose esters, cross-linked cellulose, grafted cellulose or ligand-coupled cellulose. Cellulose fiber chromatography (called Fibro chromatography; Cytiva, Sweden) is an ultrafast chromatography purification with short processing time and high productivity, which utilizes the high flow rate and high capacity of cellulose fibers. When the support of the chromatographic material comprises cellulose fibers such as Fibro, for the purpose of separating adeno-associated virus capsids, the suitable pore diameter in the cellulose fibers is greater than 25nm The minimum pore diameter (i.e., greater than the diameter of the capsid to be separated) is in the range of up to about 5μm The maximum pore diameter range, such as about 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0μm.
[0203] The term "membrane chromatography" has its conventional meaning in the field of bioprocessing. In membrane chromatography, there is a combination of a component (such as a single molecule, an associate or a particle) of a fluid and a solid surface in contact with the fluid. By convective transport, the active surface of the solid phase is accessible to molecules. The advantage of membrane adsorbers relative to packed chromatographic columns is that they are suitable for running at much higher flow rates. This is also referred to as convection-based chromatography. Convection-based chromatographic matrix includes any matrix, wherein a hydraulic pressure difference is applied between the inflow and outflow of the matrix to force the perfusion of the matrix, thereby realizing the substantially convective transport of material into the matrix or from the matrix outward, which occurs very quickly at high flow rates. Convection-based chromatography and membrane adsorbers are described, for example, in US20140296464A1, US20160288089A1, WO2018011600A1, WO2018037244A1, WO2013068741A1, WO2015052465A1, US7867784B2, which are hereby incorporated by reference in their entirety.
[0204] In the pre-screening method, the method for separating completely packaged capsids from incompletely packaged adeno-associated virus capsids, and the use of a chromatographic material for separating complete capsids from empty capsids disclosed herein, the chromatographic material mentioned can advantageously be a polishing chromatographic material, which means that the chromatographic material is used in a polishing step.
[0205] The term "polishing step" in the context of liquid chromatography refers to the final purification step, in which trace impurities are removed to leave an active, safe product. Impurities removed during the polishing step are often conformational isomers of the target molecule, i.e. forms of the target molecule with a specific molecular conformation or suspected leakage products. The polishing step may alternatively be referred to as a "secondary purification step".
[0206] Furthermore, the liquid samples respectively added in step (a), step (e) and step (I) of the methods disclosed herein may advantageously be pre-purified liquid samples.
[0207] The present disclosure also provides a method for separating completely packaged adeno-associated virus capsids from incompletely packaged adeno-associated virus capsids, which comprises performing steps (a)-(g) as described in detail above or, optionally, steps (I)-(III), the method further comprising step (a1), which comprises pre-purifying the adeno-associated virus capsids by isolating the adeno-associated virus capsids from a cell culture harvest containing the adeno-associated virus capsids, thereby obtaining a pre-purified liquid sample containing the adeno-associated virus capsids, and then adding the pre-purified liquid sample containing the adeno-associated virus capsids to the chromatographic material according to step (a), step (e) or step (I) of the method described above, respectively.
[0208] Such a pre-purification step (a1) may alternatively be referred to as a "capture step" and refers to the initial step of the separation procedure in the context of liquid chromatography. Most commonly, the capture step includes clarification (e.g., by filtration, centrifugation or precipitation), and often also includes concentration and / or stabilization of the sample, and significant purification from soluble impurities, for example by applying chromatography after clarification, concentration and stabilization of the sample. After the capture step, an intermediate purification may follow, which will further reduce the residual amount of impurities such as host cell proteins, DNA, viruses, endotoxins, nutrients, components of the cell culture medium (e.g., defoamers and antibiotics), and product-related impurities (e.g., aggregates, misfolded species, and aggregates).
[0209] Such a pre-purification step may include subjecting the cell culture harvest containing the adeno-associated virus capsids to one or more of the following non-limiting examples of purification methods:
[0210] (i) affinity chromatography,
[0211] (ii) ion exchange chromatography,
[0212] (iii) precipitation or tangential flow filtration (TFF) followed by size exclusion chromatography, for example by using, for example, Capto Core 400 chromatography material (Cytiva, Sweden), which binds the flowthrough of the capsids to the chromatography material in combination with the impurities,
[0213] (iv) TFF followed by ion exchange chromatography, and
[0214] (v) TFF followed by ion exchange chromatography and Capto Core.
[0215] Non-limiting examples of chromatographic materials suitable for use in the pre-purification step include affinity chromatography materials, ion exchange chromatography materials, and size exclusion chromatography materials, respectively. The chromatographic materials can be functionalized with positively charged groups such as quaternary amino, quaternary ammonium or amine groups or negatively charged groups such as sulfonate or carboxylate groups. The chromatographic materials can be functionalized with ion exchange groups, affinity peptide / protein-based ligands, hydrophobic interaction ligands, IMAC ligands, or DNA-based ligands such as Oligo dT.
[0216] As used herein, the term "cell culture" refers to a culture of cells or a group of cells being cultured, wherein the cells may be any type of cells, such as bacterial cells, viral cells, fungal cells, insect cells or mammalian cells. The cell culture may be unclarified, i.e., containing cells, or may be cell-depleted, i.e., containing no cells or containing very few cells but containing biomolecules released from the cells before the cells were removed. Furthermore, an unclarified cell culture may contain intact cells, disrupted cells, cell homogenates and / or cell lysates.
[0217] The term "cell culture harvest" is used herein to refer to a cell culture that has been harvested and removed from the container or device in which the cells were cultured.
[0218] The term "separation device" has its conventional meaning in the field of bioprocessing and should be understood to encompass any type of separation device capable of and suitable for separating and purifying a compound from a fluid containing by-products from the production of the compound. The separation device may comprise a separation matrix, as further defined elsewhere herein.
[0219] Non-limiting examples of separation devices suitable for use in the purification step according to the disclosed method include chromatographic columns and membrane devices, as further described elsewhere herein. Such separation devices may suitably comprise a chromatographic material in the form of a strong anion exchange chromatographic material comprising a ligand as defined by formula I, II or III, as described in detail elsewhere herein.
[0220] Non-limiting examples of separation devices suitable for use in the capture step or pre-purification step as described herein are filtration devices, chromatography columns and membrane devices. Chromatographic columns suitable for use in the capture step can, for example, be packed with affinity chromatography materials, ion exchange chromatography materials, mixed mode chromatography materials or hydrophobic interaction chromatography materials.
[0221] The method disclosed herein for separating completely packaged adeno-associated virus capsids from incompletely packaged adeno-associated virus capsids may further comprise subjecting the eluate fractions containing the adeno-associated virus capsids containing complete packaged genetic material eluted in step (g) or step (III) of the method described above to one or more of the following steps:
[0222] h1) concentrating the adeno-associated virus capsids to a pharmaceutically relevant dose,
[0223] h2) replacing the buffer used in step (b) / (g) of the method with a pharmaceutically acceptable buffer, and / or
[0224] h3) sterilizing the eluate fraction containing the adeno-associated virus capsid,
[0225] Thereby, a pharmaceutical composition comprising adeno-associated virus capsid is obtained.
[0226] It will be understood by those skilled in the art that a pharmaceutically relevant dosage will depend on a variety of factors such as, but not limited to, the disease or condition to be treated and the weight and condition of the subject to be treated with the pharmaceutical composition.
[0227] Pharmaceutically acceptable buffers are well known in the art and can be readily selected by a skilled artisan.
[0228] In order for the resulting composition to meet all regulatory requirements for pharmaceutical compositions, generally all three steps h1-h3 listed above must be performed.
[0229] In the method disclosed above, the adeno-associated virus capsid can advantageously be adeno-associated virus serotype 1 (AAV1), adeno-associated virus serotype 2 (AAV2), adeno-associated virus serotype 3 (AAV3), adeno-associated virus serotype 4 (AAV4), adeno-associated virus serotype 5 (AAV5), adeno-associated virus serotype 6 (AAV6), adeno-associated virus serotype 7 (AAV7), adeno-associated virus serotype 8 (AAV8), adeno-associated virus serotype 9 (AAV9) or adeno-associated virus serotype 10 (AAV10) or a variant thereof.
[0230] The term "variant" with respect to adeno-associated virus (AAV) serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 as listed above is intended to refer to a modified or engineered AAV in which the capsid structure has been modified to improve clinical performance, such as clinical performance for a specific target organ. As a non-limiting example, an AAV8 variant comprises a capsid portion of AAV8 and may also comprise a capsid portion of other AAV serotypes such as AAV5 in addition to AAV8. However, the AAV8 variant as mentioned herein must retain significant structural similarity to the unmodified AAV8 capsid, such as retaining at least 50%, such as 60%, 70%, 80% or 90% of the outer surface structure of the unmodified AAV8 capsid. The same applies to variants of AAV serotypes 1, 2, 3, 4, 5, 6, 7, 9 or 10 compared to unmodified AAV serotypes 1, 2, 3, 4, 5, 6, 7, 9 or 10, respectively. In addition, as a non-limiting example, in the context of purification or isolation of variants of AAV8, a "variant" is defined herein as an adeno-associated virus having a functionally equivalent ability to bind to a ligand of a specified chromatographic material compared to the ability of the original AAV8 to bind to the specified chromatographic material. The same applies to variants of AAV serotypes 1, 2, 3, 4, 5, 6, 7, 9 or 10 compared to the original AAV serotypes 1, 2, 3, 4, 5, 6, 7, 9 or 10, respectively. The specified chromatographic material can, for example, be a strong anion exchange chromatographic material, as disclosed in more detail elsewhere herein. Variants of adeno-associated viruses can be obtained, for example, by spontaneous mutation or engineered modification (i.e., obtained by human interaction) of one or more nucleotides of the genome of the adeno-associated virus.
[0231] According to the currently preferred embodiment, Figure 2 In the separation method illustrated in , the chromatographic material is defined by Formula IV:
[0232]
[0233] wherein the elution buffer of steps (b), (f), optionally (f') and (g) comprises sodium acetate. The method can be applied to the separation of AAV capsids of any serotype or variant as described above. In particular, the capsid to be separated can be a capsid of the AAV9 serotype or a variant thereof.
[0234] According to another currently preferred embodiment, in Figure 3 In the separation method illustrated in , the chromatographic material is defined by Formula IV:
[0235]
[0236] wherein the elution buffer of steps (II), optionally (II') and (III) comprises sodium acetate. The method can be applied to the separation of AAV capsids of any serotype or variant as described above. In particular, the capsid to be separated can be a capsid of the AAV9 serotype or a variant thereof.
[0237] The present disclosure also provides a use of an anion exchange chromatography material for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, wherein the anion exchange chromatography material comprises a support, a ligand, and a surface extender that connects the ligand to the support, and is defined by Formula IV:
[0238]
[0239] The method comprises determining elution conditions suitable for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material,
[0240] The elution conditions are determined by performing the following steps:
[0241] a. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids with a concentration of 100 adeno-associated virus capsids / ml is added to the chromatographic material, wherein at least 5%, for example 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material;
[0242] b. eluting adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein the conductivity starts at about 0 to about 5 mS / cm and increases by about 0.5 to about 3 mS / cm per step, such as by about 1 to about 2 mS / cm per step, such as by about 1.2 to about 1.5 mS / cm per step, at least up to and including the conductivity at which adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material have been eluted from the chromatography material;
[0243] c. based on the elution curve obtained in step (b), determining a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not completely package genetic material, and
[0244] d. Based on the elution curve obtained in step (b), determine a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that fully package genetic material.
[0245] In the use disclosed herein, the adeno-associated virus capsids that completely package genetic material can be separated from the adeno-associated virus capsids that incompletely package genetic material by performing steps (a) to (d) as described above, and further by performing the following steps:
[0246] e. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids with a concentration of 100 adeno-associated virus capsids / ml is added to the chromatographic material, wherein at least 5%, for example 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material, and the liquid sample is derived from the cell culture harvest from which the liquid sample of step (a) is derived;
[0247] f. eluting adeno-associated viral capsids that are incompletely packaged with genetic material by applying an elution buffer having a first value of conductivity or a conductivity-related parameter as determined in step (c); and
[0248] g. eluting the adeno-associated virus capsids intactly packaged with genetic material by applying an elution buffer having a second value of conductivity or a conductivity-related parameter as determined in step (d);
[0249] in
[0250] (i) the duration of step (f) is at least 3 times, for example 4 times, the duration of step (g), and / or
[0251] (ii) the method comprises a step (f') between step (f) and step (g), wherein step (f') comprises applying a further step elution and / or an increasing conductivity gradient between a first value and a second value of the conductivity or a conductivity-related parameter, and the duration of steps (f) and (f') is at least 3 times, for example 4 times, the duration of step (g).
[0252] Preferably, the elution buffer of step (b) of the above-mentioned use, and where appropriate, the elution buffer of steps (f) and (g) of the above-mentioned use, comprises sodium acetate. The use can be applied to separate AAV capsids of any serotype or variant as described above. In particular, the capsid to be separated can be a capsid of the AAV9 serotype or a variant thereof.
[0253] A device or composition "comprising" one or more recited components may also include other components not expressly recited. The term "comprising" includes "consisting essentially of" as a subset, which means that the device or composition has the listed components without the presence of other features or components. Similarly, a method "comprising" one or more recited steps may also include other steps not expressly recited.
[0254] The singular forms "a" and "an" should be construed as including the plural forms as well.
[0255] Example
[0256] Example 1: Separation of capsids of serotypes AAV2, AAV5, AAV8 and AAV9 on an anion exchange chromatographic material using an increasing sodium acetate step gradient for elution
[0257] Chromatographic materials
[0258] The following currently available anion exchange chromatography materials provide improved results, as further described below:
[0259] Capto Q (Cytiva, Sweden):
[0260] Ligand: Quaternary amine
[0261] Particle size, d 50V :~90μm
[0262] Matrix: Highly cross-linked agarose with dextran surface extenders
[0263] Ion capacity: 0.16-0.22mmol Cl - / ml medium
[0264] pH stability, operating range: 2-12.
[0265] CaptoDEAE (Cytiva, Sweden):
[0266] Ligand: Diethylaminoethyl, partially quaternized amine groups
[0267] Particle size, d 50V :~90μm
[0268] Matrix: Highly cross-linked agarose with dextran surface extenders
[0269] Ion capacity: 0.29-0.35mmol Cl - / ml medium
[0270] pH stability, operating range: 2-9.
[0271] In addition, the currently available Capto Q ImpRes (Cytiva, Sweden) was also tested as described below. The support material of the ImpRes resin consists of essentially spherical particles or beads with a diameter of 40 μm.
[0272] Equipment and samples
[0273] Each resin was packed into a Tricorn 5 column (2 mL) according to the packing instructions. The Pure P25 system (P25-20031) was run at a flow rate of 1 CV / min (i.e., 2 mL / min) with the system's mixer disconnected to minimize dead volume and obtain a steep conductivity step. The sample was applied to the previously equilibrated column using a capillary loop. Typically, the sample applied to each resin was approximately 5 x 10 12 The concentration of each AAV capsid contains affinity purified or affinity and size exclusion purified AAV2, AAV5, AAV8 or AAV9, which contains a mixture of intact capsids and empty capsids (>5% intact capsids, as follows: AAV2 7-10%, AAV5 47%, AAV8 11-35%, AAV9 40%). The material needs to have a low conductivity (1-3mS / cm) to ensure binding of AAV to the anion exchange ligand.
[0274] The 280 and 260 nm UV absorbance was monitored during the run and the 260 / 280 ratio was used as a diagnostic tool to navigate the chromatogram and distinguish between the intact capsid population and the empty capsid population. The chromatograms were analyzed using Unicorn's evaluation package. A 260 / 280 ratio above 1.2 was considered to indicate 100% intact capsids, and a 260 / 280 ratio of approximately or below 0.6-0.7 was considered to indicate 100% empty capsids. If necessary, a blank run was performed using buffer without AAV to subtract any background signal to ensure removal of potential UV signals from the buffer.
[0275] Process conditions and results
[0276] Acetate buffer at pH 4.5 and 5 was used with different elution salts (NaCl, NaOAc, NH 4 Cl or NH 4 SO 4 , up to 500 mM) and additive salts (MgCl 2 The currently available cation exchange resin Capto S and the prototype cation exchange resin Capto CM Dx ImpRes were evaluated by applying isocratic or continuous gradient elution, respectively. None of the above mentioned conditions or resins produced a good baseline separation of intact and empty capsids (data not shown).
[0277] Each currently available anion exchange resin with a dextran extender: Capto DEAE (partial strong anion exchange) and Capto Q (strong anion exchange) was evaluated using a buffer system consisting of buffer A and buffer B, both containing 20 mM Bis-Tris propane (BTP) pH 9.0 and 2 mM MgCl 2 , and buffer B additionally contained 250 mM sodium acetate (NaOAc) as elution salt.
[0278] exist Figure 4-7 In the y-axis on the right hand side of each chromatogram represents the percentage of buffer B contained in the resulting elution buffer during elution from the chromatography material (the remainder being buffer A).
[0279] Pre-screening methods
[0280] The step gradient applied in the prescreening method comprised short steps (3CV) of increasing NaOAc concentration, more specifically 12.5 mM increments per step, i.e. 250 mM NaOAc in buffer B with a concentration increase of 5% per step, which corresponds to a conductivity increase of approximately 1.2-1.5 mS / cm per step.
[0281] Equilibration: 5CV Buffer A
[0282] Injection: Empty loop, use 3 ml buffer A
[0283] Wash: 5 CV Buffer A
[0284] Step gradient: 5% increasing step of buffer B, 3CV each
[0285] Wash: 100% buffer B, 5 CV
[0286] Re-equilibration: 5 CV buffer A
[0287] Capto Q
[0288] Figure 4 A shows the results of the pre-screening method for AAV9 separated on Capto Q resin. Multiple peaks close to each other can be seen in the chromatogram ( Figure 4 A's peak numbers 1, 2 and 3). Figure 4 Peaks No. 1, 2, and 3 of A contained intact capsids and empty capsids at different ratios. Peak No. 1 contained mainly empty capsids, while Peaks No. 2 and 3 contained mainly intact capsids. The UV260 / 280 ratios were as follows: 0.62 for Peak 1, 1.21 for Peak 2, and 1.26 for Peak 3.
[0289] according to Figure 4A chromatogram, a first value of conductivity was determined to be suitable for eluting empty capsids. The determined first value of conductivity corresponds to the concentration of NaOAc applied when eluting the first peak containing empty and / or intact capsids, peak number 1. The first value of conductivity was selected to be about 1.2-1.5 mS / cm, corresponding to 5% buffer B, i.e. 12.5 mM NaOAc.
[0290] Also based on Figure 4 A, the second value of conductivity is determined to be suitable for eluting intact capsids. The selected second value of conductivity corresponds to a NaOAc concentration that is higher than the NaOAc concentration applied when eluting the last peak containing empty and / or intact capsids, peak number 3. The selected second value of conductivity is about 7.2-9.0 mS / cm, corresponding to 30% buffer B, i.e., 75 mM NaOAc.
[0291] Note here that the second value of conductivity can be selected instead to correspond to the NaOAc concentration applied when eluting the last peak containing empty and / or intact capsids, or any higher value. Thus, the second value of conductivity can be about 3.6-4.5 mS / cm, corresponding to 15% buffer B applied when eluting peak number 3, i.e. 37.5 mM NaOAc, or any higher value, i.e. ≥ 3.6 mS / cm, corresponding to ≥ 37.5 mM NaOAc.
[0292] Figure 5 A shows the results of the pre-screening method for AAV8 separated on Capto Q resin. Multiple peaks close to each other can be seen in the chromatogram ( Figure 5 A's peak numbers 1, 2 and 3). Figure 5 Peaks No. 1, 2, and 3 of A contained intact capsids and empty capsids at different ratios. Peaks No. 1 and 2 contained mainly empty capsids, while Peak No. 3 contained mainly intact capsids. The UV260 / 280 ratios were as follows: 0.6 for Peak 1, 0.66 for Peak 2, and 1.3 for Peak 3.
[0293] according to Figure 5 A, a first value of conductivity was determined to be suitable for eluting empty capsids. The determined first value of conductivity corresponds to the concentration of NaOAc applied when eluting the first peak containing empty and / or intact capsids, peak number 1. The first value of conductivity was selected to be about 7.2-9.0 mS / cm, corresponding to 30% buffer B, i.e. 75 mM NaOAc.
[0294] Also based on Figure 5A, the second value of conductivity is determined to be suitable for eluting intact capsids. The selected second value of conductivity corresponds to a NaOAc concentration that is higher than the NaOAc concentration applied when eluting the last peak containing empty and / or intact capsids, peak number 3. The selected second value of conductivity is about 24-30 mS / cm, corresponding to 100% buffer B, i.e., 250 mM NaOAc.
[0295] Note here that the second value of conductivity can be selected instead to correspond to the NaOAc concentration applied when eluting the last peak containing empty and / or intact capsids, or any higher value. Thus, the second value of conductivity can be about 9.6-12.0 mS / cm, corresponding to 40% of buffer B, i.e., 100 mM NaOAc, applied when eluting peak number 3, or any higher value, i.e., ≥ 9.6 mS / cm, corresponding to ≥ 100 mM NaOAc.
[0296] CaptoDEAE
[0297] Figure 6 Results are shown for a pre-screening method for elution of AAV9 on Capto DEAE resin.
[0298] The same conditions described above for Capto Q were used in the prescreening procedure (buffer A: 20 mM BTP pH 9.0, 2 mM MgCl 2 ; Buffer B: Buffer A + 250 mM NaOAc), but using a 4% increasing elution step of Buffer B (3CV each), AAV9 empty capsids eluted in the flow-through, while AAV9 complete capsids eluted in the first step of the step gradient. In the first peak (i.e., the flow-through peak), the UV 260:280 ratio was 0.76, indicating that it was mainly empty AAV9 capsids, but there were also a small amount of complete capsids. In the second peak, the UV260:280 ratio was 1.3, indicating high purity AAV9 complete capsids ( Figure 6 ).
[0299] according to Figure 6 In the chromatogram, the first value of the conductivity suitable for eluting AAV9 empty capsids was determined to be approximately 0 mS / cm, corresponding to 0% buffer B, and the second value of the conductivity suitable for eluting AAV9 complete capsids was determined to be approximately 1 mS / cm, corresponding to 4% buffer B, i.e., 10 mM NaOAc.
[0300] Two-step elution method
[0301] The first and second values of conductivity as determined in the pre-screening method described above are applied to the subsequent two-step elution method for separating intact capsids from empty capsids.
[0302] Equilibration: 5CV Buffer A
[0303] Injection: Empty loop, use 3 ml buffer A
[0304] Wash: 5 CV Buffer A
[0305] Step elution: Step 1, first value of conductivity, 20CV; Step 2, second value of conductivity, 5CV
[0306] Re-equilibration: 5 CV buffer A
[0307] Capto Q
[0308] All serotypes tested (AAV2, AAV5, AAV8 and AAV9) resulted in good separation of intact and empty capsids when using Capto Q resin.
[0309] Figure 4 B shows the results of a two-step elution method for AAV9 on Capto Q resin, applying a first value of conductivity corresponding to 5% buffer B in the first step and a second value of conductivity corresponding to 30% buffer B in the second step, as described above. Intact (F) and empty (E) capsids, and UV260:280 ratios are shown in Figure 4 In B.
[0310] Figure 5 B shows the results of a two-step elution method for AAV8 on Capto Q resin, using 30% buffer B in the first step and 100% buffer B in the second step, as described above. Intact (F) and empty (E) capsids, and UV260:280 ratios are shown in Figure 5 In B.
[0311] Among the AAV9 samples tested, peaks containing empty and / or intact capsids were also analyzed by qPCR, showing very low amounts (0.3%) of intact capsids in the empty peak and an overall 91% recovery of viral genomes in the intact peak.
[0312] CaptoDEAE
[0313] AAV9 capsids were separated on Capto DEAE resin by applying the conditions established in the pre-screening method described above, i.e. a first value of conductivity corresponding to 0% of buffer B and a second value of conductivity corresponding to 4% of buffer B. The resulting separation of intact and empty capsids is shown in Figure 6 (described above).
[0314] Capto QImpRes (without dextran extender)
[0315] Capto Q ImpRes resin was evaluated under the same conditions as those described above for the separation of AAV9 and AAV5, respectively, except that a flow rate of 1 ml / min was applied due to the high delta column pressure. The resin was ineffective for AAV5, but was fully effective for prescreening and two-step elution to separate AAV9 complete capsids from AAV9 empty capsids (results not shown). However, Capto Q ImpRes (without extender) did not bind to AAV9 empty capsids (which were thus eluted in the flow-through) and only weakly bound to AAV9 complete capsids, thus providing a less robust separation method than Capto Q (with extender).
[0316] Example 2: Separation of capsids of serotypes AAV5 and AAV9 on an anion exchange chromatographic material using an increasing magnesium chloride step gradient for elution
[0317] Capto Q resin was evaluated for the separation of AAV9 and AAV5, respectively, by applying the prescreening method described in Example 1 followed by a two-step elution, except that both buffer A and buffer B of the buffer system contained 20 mM Bis-Tris propane (BTP) pH 7.0 (AAV5) or pH 9.5 (AAV9), 1% sucrose and 0.1% Pluronic, and buffer B additionally contained 20 mM MgCl 2 .
[0318] Pre-screening methods
[0319] Equilibration: 5CV Buffer A
[0320] Injection: Empty loop, use 3 ml buffer A
[0321] Wash: 5 CV Buffer A
[0322] Step gradient elution: 5% increasing step of buffer B, 3CV each
[0323] Wash: 5CV 100% Buffer B
[0324] Re-equilibration: 5 CV buffer A
[0325] Figure 7 A shows the results of the pre-screening method for AAV5 separated on Capto Q resin. In the chromatogram, multiple peaks close to each other can be seen ( Figure 7A peak number 1, 2, 3 and 4). Peak numbers 1, 2, 3, 4 and 5 contain different ratios of complete capsids and empty capsids. Peak numbers 1 and 2 contain mainly empty capsids, while peak numbers 3, 4 and 5 contain mainly complete capsids. The UV260 / 280 ratios are as follows: 0.68 for peak 1, 0.87 for peak 2, 1.14 for peak 3, 1.1 for peak 4, and 1 for peak 5.
[0326] according to Figure 7 A, the first value of conductivity is determined to be suitable for eluting empty capsids. The first value of conductivity determined corresponds to the MgCl applied when eluting the first peak containing empty and / or intact capsids, i.e., peak number 1. 2 The first value of conductivity selected was about 4.6 mS / cm, corresponding to 50% buffer B, i.e. 10 mM MgCl 2 .
[0327] Also based on Figure 7 A, the second value of conductivity was determined to be suitable for eluting intact capsids. The second value of conductivity was selected to correspond to the MgCl applied when eluting the last peak containing empty and / or intact capsids, i.e., peak number 5. 2 The same concentration of MgCl 2 The second value of conductivity selected was about 5.3 mS / cm, corresponding to 70% buffer B, i.e. 14 mM MgCl 2 .
[0328] Alternatively, the second value of conductivity may be selected to be higher than the MgCl applied when eluting the last peak containing empty and / or intact capsids, i.e., peak number 5. 2 concentration.
[0329] Two-step elution method
[0330] The first and second values of conductivity as determined in the pre-screening method described above are applied to the subsequent two-step elution method for separating intact capsids from empty capsids.
[0331] Equilibration: 5CV Buffer A
[0332] Injection: Empty loop, use 3 ml buffer A
[0333] Wash: 5 CV Buffer A
[0334] Step elution: Step 1, 50% buffer B, 20CV; Step 2, 70% buffer B, 20CV
[0335] Re-equilibration: 5 CV buffer A
[0336] Figure 7B shows the results of a two-step elution method for AAV5 on Capto Q resin, using 50% buffer B in the first step and 70% buffer B in the second step, as described above. Intact (F) and empty (E) capsids, and UV260:280 ratios are shown in Figure 7 In B. Here, considering that the second peak (intact capsids) is very sharp (hardly any tailing), it should be noted that by applying a shorter step 2 duration, corresponding to 5 CV (as in the previous example), the two-step elution method is equally efficient.
[0337] Alternative buffer systems
[0338] Alternative buffer systems were also tested, including buffer A with a higher pH and buffer B, both containing 20 mM Bis-Tris propane (BTP) pH 9.5, 1% sucrose and 0.1% Pluronic, with buffer B additionally containing 30 mM MgCl 2 , i.e., a higher concentration of MgCl 2 Here, in a pre-screening approach, increasing MgCl 2 The first and second conductivity values determined correspond to 68% and 90% of buffer B, respectively. The conductivity values were then applied to a two-step elution method.
[0339] The above conditions resulted in successful baseline separation of AAV5 (results for alternative buffer systems not shown). AAV9 bound less strongly to anion exchange, however conditions including higher pH (e.g. 9.5) and application of a small conductivity increment elution step resulted in acceptable performance (results not shown).
[0340] Example 3: Isolation of AAV9 capsids under variable conditions
[0341] An experimental design for separating fully packaged AAV9 capsids from empty and partially packaged AAV9 capsids was performed using the apparatus and samples as in Examples 1 and 2 above, and further by using an anion exchange chromatography material as in Examples 1 and 2, with the following changes:
[0342] In terms of capsid:
[0343] 1. AAV9-based modified capsid variants
[0344] 2. An AAV9 capsid having an insert different from and longer than the insert included in the capsids of Example 1 and Example 2, the former insert being green fluorescent protein (GFP).
[0345] In terms of surface extenders:
[0346] 1) Dextran of different sizes (kDa) (T10, T70, T250);
[0347] 2) different amounts of dextran;
[0348] 3) Use alternatives to dextran, such as glycidol-based polyols.
[0349] In terms of ligand density:
[0350] 1) Capto Q: 60-160, 220-260μmol / mL;
[0351] 2) Capto DEAE: 150-290, 350-400μmol / mL.
[0352] In terms of chromatography material support:
[0353] 1) Smaller resin bead size: 35-90 μm;
[0354] 2) Resin beads with larger pore sizes than Capto Q and Capto DEAE;
[0355] 3) Magnetic beads in batch mode.
[0356] In ligand chemistry:
[0357] 1) Capto DEAE ligands with different levels of quaternization (ligands according to formula III);
[0358] 2) Capto Q analogs (ligands according to formula I):
[0359] a. R1 and R2 are ethyl; R3 is methyl;
[0360] b. R1 and R2 are methyl groups; R3 is CH2CHOHCH3;
[0361] 3) Capto DEAE analogs (ligands according to formula II):
[0362] am=1;n=1;R1, R2, R3 and R4=methyl;R5=H;
[0363] bm=1; n=1; R1, R2, R3 and R4=methyl; R5=CH2CHOHCH3.
[0364] 4) Capto DEAE analogs (ligands according to formula III):
[0365] an=1; R1, R2, R3 and R4=methyl; R5=H or absent.
[0366] In terms of buffer and elution conditions:
[0367] 1) MgCl at different concentrations from 1 to 20 mM 2 ;
[0368] 2) Different lyophilic salts were used for elution, step gradient 0.1-1 M, with or without MgCl as in 1) 2 ;
[0369] 3) Different pH step gradients pH 4-10, with or without MgCl as in 1) 2 ;
[0370] 4) Different buffers:
[0371] a.Tris
[0372] bN-Methyldiethanolamine
[0373] 5) Linear gradient elution, with pH, lyophilic salt for elution, MgCl as in 1), 2), 3) and 4). 2 ;
[0374] 6) an additional step between the two elution steps of the two-step elution scheme according to Example 1, such as a third elution step or a linear elution gradient;
[0375] 7) conditions suitable for flow-through separations, where one analyte binds to the chromatographic material and the other does not (anion exchange resins bind more strongly to intact capsids than to empty capsids; thus empty capsids can elute with the flow-through);
[0376] 8) All of the above, with or without additives such as sucrose (0.1-5%) and poloxamer 188 detergent (0.01-1%).
[0377] Example 4: Isolation of capsids from different adeno-associated virus serotypes under variable conditions
[0378] The experimental design for separating intact capsids from empty capsids of adeno-associated virus serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 and AAV10 and variants thereof was performed according to the variable conditions of Examples 1-4 above.
[0379] It is understood that the present disclosure is not limited to the exemplary embodiments thereof described above and that several conceivable modifications of the disclosure are possible within the scope of the appended claims.
[0380] References
[0381] Weihong Qu et al., Scalable Downstream Strategies for Purification of Recombinant Adeno - Associated Virus Vectors in Light of the Properties, Current Pharmaceutical Biotechnology 2015 Aug; 16(8):684–695
[0382] Hejmowski Adam L et al., Novel anion exchange membrane chromatography method for the separation of empty and full adeno - associated virus, Biotechnol. J. 2021; 2100219.
[0383] https: / / doi.org / 10.1002 / biot.202100219
[0384] Xiaotong Fu et al., Analytical Strategies for Quantification of Adeno - Associated Virus Empty Capsids to Support Process Development, Human gene therapy methods, 2019, 30(4):144 - 152
[0385] Moelbert Susanne et al., Kosmotropes and chaotropes: modelling preferential exclusion, binding and aggregate stability, Biophysical Chemistry, 2004 Dec, 112(1):45 - 57
[0386] Hyde A M et al., General Principles and Strategies for Salting - Out Informed by the Hofmeister Series, Organic Process Research & Development, 2017, 21(9):1355–1370。
Claims
1. A method for determining elution conditions suitable for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method comprising: The following steps are involved: a. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 50% adeno-associated virus capsids / ml is added to a strong or partially strong anion exchange chromatography material, the chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids, wherein at least 5% of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material, wherein the chromatography material comprises a surface extension agent that connects the ligand to the support, wherein the surface extension agent is a polymer, wherein the polymer is selected from: (i) polymers having a naturally occurring backbone, such as a polysaccharide, for example starch, cellulose, dextran or agarose, and (ii) polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether; b. eluting the adeno-associated virus capsids that do not completely package the genetic material and the adeno-associated virus capsids that completely package the genetic material from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein the conductivity starts at about 0 to about 5 mS / cm and increases by about 0.5 to about 3 mS / cm per step, at least up to and including the conductivity at which the adeno-associated virus capsids that do not completely package the genetic material and the adeno-associated virus capsids that completely package the genetic material have been eluted from the chromatography material; c. based on the elution curve obtained in step (b), determining a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not completely package genetic material, and d. Based on the elution curve obtained in step (b), determine a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that fully package genetic material.
2. The method according to claim 1, wherein the step gradient of increasing conductivity in step (b) is a step gradient of increasing salt concentration, optionally wherein the conductivity-related parameter in steps (c) and (d) is salt concentration.
3. The method of claim 2, wherein the salt is a kosmotropic salt.
4. The method according to claim 2 or 3, wherein the salt comprises (i) selected from CO 3 2- 、SO 4 2- , S 2 O 3 2- , H 2 PO 4 - , HPO 4 2- , acetate - , Citrate - and Cl - anion, and (ii) selected from NH 4 + , K + 、Na + and Li + A cation; optionally wherein the salt is sodium acetate.
5. A method according to any one of the preceding claims, wherein step (b) comprises adding a volume of elution buffer corresponding to about 1 to about 10 volumes of chromatography material per step of the step gradient.
6. A method for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method comprising steps (a) to (d) of claim 1, and further comprising: The following steps are involved: e. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 10% adeno-associated virus capsids / ml of adeno-associated virus capsids is added to the chromatographic material as defined in step (a), wherein at least 5% of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material, the liquid sample being derived from the cell culture harvest from which the liquid sample of step (a) is derived; f. eluting adeno-associated viral capsids that are incompletely packaged with genetic material by applying an elution buffer having a first value of conductivity or a conductivity-related parameter as determined in step (c); and g. eluting the adeno-associated virus capsids intactly packaged with genetic material by applying an elution buffer having a second value of conductivity or a conductivity-related parameter as determined in step (d); in (i) the duration of step (f) is at least 3 times the duration of step (g), and / or (ii) the method comprises a step (f') between step (f) and step (g), wherein step (f') comprises applying a further step elution and / or an increasing conductivity gradient between a first value and a second value of the conductivity or a conductivity-related parameter, and the duration of steps (f) and (f') is at least 3 times the duration of step (g).
7. A method according to claim 6, wherein the elution buffer comprises salt and the step gradient of increasing conductivity in step (b) is a step gradient of increasing salt concentration, optionally wherein the conductivity-related parameter in steps (c), (f) and (g) is salt concentration.
8. The method of claim 7, wherein the salt is a kosmotropic salt.
9. The method according to claim 7 or 8, wherein the salt comprises (i) selected from CO 3 2- 、SO 4 2- , S 2 O 3 2- , H 2 PO 4 - , HPO 4 2- , acetate - , Citrate - and Cl - anion, and (ii) selected from NH 4 + , K + 、Na + and Li + A cation; optionally wherein the salt is sodium acetate.
10. The method according to any one of claims 6 to 9, wherein step (b) comprises adding a volume of elution buffer corresponding to about 1 to about 10 volumes of chromatography material per step of the step gradient.
11. A method for separating adeno-associated virus capsids that completely package genetic material from adeno-associated virus capsids that incompletely package genetic material, the method include: (I) will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids containing 100% adeno-associated virus capsids / ml of adeno-associated virus capsids is added to a strong or partially strong anion exchange chromatography material, the chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids, wherein at least 5% of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material, wherein the chromatographic material comprises a surface extending agent linking the ligand to the support, wherein the surface extending agent is a polymer, wherein the polymer is selected from: (i) polymers having a naturally occurring backbone, such as a polysaccharide, for example starch, cellulose, dextran or agarose, and (ii) polymers with synthetic backbones, such as polyvinyl alcohol, polyacrylamide, polymethacrylamide or polyvinyl ether; (II) eluting adeno-associated virus capsids that incompletely package genetic material by applying an elution buffer having a predetermined first value of conductivity or a conductivity-related parameter; (III) eluting the intact adeno-associated virus capsids packaging the genetic material by applying an elution buffer having a predetermined second value of conductivity or a conductivity-related parameter; The predetermined first and second values of conductivity or a conductivity-related parameter are present in a sample having a purity of at least 90% and a concentration of at least 10 12 adeno-associated virus capsids / ml, wherein at least 5% of the adeno-associated virus capsids are adeno-associated virus capsids that are intact and packaged with genetic material, the liquid sample being derived from the cell culture harvest from which the liquid sample of step (I) is derived; optionally having been determined by performing the method of steps (a) to (d) of claim 1; in (i) the duration of step (II) is at least 3 times the duration of step (III), and / or (ii) the method comprises a step (II') between step (II) and step (III), wherein step (II') comprises applying a step elution and / or an increasing conductivity gradient between a first value and a second value of conductivity or a conductivity-related parameter, and the duration of steps (II) and (II') is at least 3 times the duration of step (III).
12. The method according to any one of the preceding claims, wherein the chromatographic material is defined by: i) Formula I: in R 1 is selected from C1-C3 alkyl, and R 2 and R 3 Independently selected from C1-C3 alkyl, CH2OH and CH2CHOHCH3; Optionally, R 1 , R 2 and R 3 Each is CH3; or ii) Formula II: in: m is an integer from 1 to 3; R 1 and R 2 Independently selected from C1-C3 alkyl; R 3 and R 4 is independently selected from C1-C3 alkyl and CH2CHOHCH3; and R 5 is selected from hydrogen, C1-C3 alkyl and CH2CHOHCH3; Provided that if m is 1, the chromatographic material is defined by Formula III: Where n is an integer from 0 to 3; The condition is that if n is 0, then R 3 and R 4 are independently selected from C1-C3 alkyl, and R 5 is hydrogen or CH2CHOHCH3; Optionally wherein the chromatographic material is defined by Formula III and comprises a combination of two or more of the following structures (i)-(iv): (i) n is 0; R 3 and R 4 is ethyl; and R 5 is hydrogen or CH2CHOHCH3; (ii) n is 1; R 1 , R 2 , R 3 , R 4 is ethyl; and R 5 is hydrogen or CH2CHOHCH3; (iii) n is 2; R 1 and R 2 Each is ethyl; R 3 and R 4 is ethyl; and R 5 is hydrogen or CH2CHOHCH3; (iv) n is 3; R 1 and R 2 Each is ethyl; R 3 and R 4 is ethyl; and R 5 It is hydrogen or CH2CHOHCH3.
13. The method according to any one of the preceding claims, wherein the surface extending agent is dextran; Optionally wherein the dextran has a molecular weight of about 10 to about 2000 kDa, such as about 40 kDa, and / or Optionally wherein the density of dextran is from about 5 to about 30 mg dextran per ml of said strong anion exchange chromatography material.
14. The method according to any of the preceding claims, wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 1 (AAV1), adeno-associated virus serotype 2 (AAV2), adeno-associated virus serotype 3 (AAV3), adeno-associated virus serotype 4 (AAV4), adeno-associated virus serotype 5 (AAV5), adeno-associated virus serotype 6 (AAV6), adeno-associated virus serotype 7 (AAV7), adeno-associated virus serotype 8 (AAV8), adeno-associated virus serotype 9 (AAV9) or adeno-associated virus serotype 10 (AAV10) or a variant thereof; Optionally wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 9 (AAV9) or a variant thereof.
15. The method according to any one of claims 6 to 10, wherein the chromatographic material is defined by formula IV: wherein the elution buffer of step (b) of claim 1 and the elution buffer of steps (f) and (g) of claim 6 comprise sodium acetate, wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 1 (AAV1), adeno-associated virus serotype 2 (AAV2), adeno-associated virus serotype 3 (AAV3), adeno-associated virus serotype 4 (AAV4), adeno-associated virus serotype 5 (AAV5), adeno-associated virus serotype 6 (AAV6), adeno-associated virus serotype 7 (AAV7), adeno-associated virus serotype 8 (AAV8), adeno-associated virus serotype 9 (AAV9) or adeno-associated virus serotype 10 (AAV10) or a variant thereof; Optionally wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 9 (AAV9) or a variant thereof.
16. The method of claim 11, wherein the chromatographic material is defined by Formula IV: wherein the elution buffer of steps (II) and (III) of claim 11 comprises sodium acetate; wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 1 (AAV1), adeno-associated virus serotype 2 (AAV2), adeno-associated virus serotype 3 (AAV3), adeno-associated virus serotype 4 (AAV4), adeno-associated virus serotype 5 (AAV5), adeno-associated virus serotype 6 (AAV6), adeno-associated virus serotype 7 (AAV7), adeno-associated virus serotype 8 (AAV8), adeno-associated virus serotype 9 (AAV9) or adeno-associated virus serotype 10 (AAV10) or a variant thereof; Optionally wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 9 (AAV9) or a variant thereof.
17. Use of an anion exchange chromatography material for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material, the chromatography material comprising a support, a ligand, and a surface extender that connects the ligand to the support, and is defined by Formula IV: The method comprises determining elution conditions suitable for separating adeno-associated virus capsids that fully package genetic material from adeno-associated virus capsids that incompletely package genetic material, The elution conditions are determined by performing the following steps: a. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids with a concentration of 100 adeno-associated virus capsids / ml is added to the chromatographic material, wherein at least 5%, such as 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material; b. eluting adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material from the chromatography material by applying an elution buffer comprising a step gradient of increasing conductivity, wherein the conductivity starts at about 0 to about 5 mS / cm and increases by about 0.5 to about 3 mS / cm per step, such as by about 1 to about 2 mS / cm per step, such as by about 1.2 to about 1.5 mS / cm per step, at least up to and including the conductivity at which adeno-associated virus capsids that do not completely package genetic material and adeno-associated virus capsids that completely package genetic material have been eluted from the chromatography material; c. based on the elution curve obtained in step (b), determining a first value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that do not completely package genetic material, and d. Based on the elution curve obtained in step (b), determine a second value of conductivity or a conductivity-related parameter suitable for eluting adeno-associated virus capsids that fully package genetic material.
18. The use according to claim 17, wherein the adeno-associated virus capsids that completely package the genetic material are separated from the adeno-associated virus capsids that incompletely package the genetic material by performing steps (a) to (d) of claim 17, and further by performing the following steps: e. will contain a purity of at least 90% and a concentration of at least 10 12 A liquid sample of adeno-associated virus capsids with a concentration of 100 adeno-associated virus capsids / ml is added to the chromatographic material, wherein at least 5%, for example 10%, of the adeno-associated virus capsids are adeno-associated virus capsids that fully package genetic material, and the liquid sample is derived from the cell culture harvest from which the liquid sample of step (a) is derived; f. eluting adeno-associated viral capsids that are incompletely packaged with genetic material by applying an elution buffer having a first value of conductivity or a conductivity-related parameter as determined in step (c); and g. eluting the adeno-associated virus capsids intactly packaged with genetic material by applying an elution buffer having a second value of conductivity or a conductivity-related parameter as determined in step (d); in (i) the duration of step (f) is at least 3 times, for example 4 times, the duration of step (g), and / or (ii) the method comprises a step (f') between step (f) and step (g), wherein step (f') comprises applying a further step elution and / or an increasing conductivity gradient between a first value and a second value of the conductivity or a conductivity-related parameter, and the duration of steps (f) and (f') is at least 3 times, for example 4 times, the duration of step (g).
19. The use according to claim 17 or 18, wherein the elution buffer of step (b) of claim 17, and also the elution buffer of steps (f) and (g) of claim 18 when dependent on claim 18, comprises sodium acetate; wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 1 (AAV1), adeno-associated virus serotype 2 (AAV2), adeno-associated virus serotype 3 (AAV3), adeno-associated virus serotype 4 (AAV4), adeno-associated virus serotype 5 (AAV5), adeno-associated virus serotype 6 (AAV6), adeno-associated virus serotype 7 (AAV7), adeno-associated virus serotype 8 (AAV8), adeno-associated virus serotype 9 (AAV9) or adeno-associated virus serotype 10 (AAV10) or a variant thereof; Optionally wherein the adeno-associated virus capsid is a capsid of adeno-associated virus serotype 9 (AAV9) or a variant thereof.
Citation Information
Patent Citations
Chromatography medium
US20140296464A1
Chromatography medium
US20160288089A1
Adsorption / separation method and a medium for adsorption / separation
US6428707B1
Process for the production of a porous cross-linked polysaccharide gel and its use as a gel filtration media and in chromatography
US6602990B1
Chromatography ligand
US7867784B2
